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ABSTRACT: This manuscript describes a metal-free strategy for the formation of lactams via selective oxidation of cyclic secondary 
and tertiary amines. Molecular iodine facilitates both chemoselective and regioselective oxidation of C-H bonds directly adjacent to 
a cyclic amine. The mild conditions, functional group tolerance and substrate scope are demonstrated using a suite of diverse small 
molecule cyclic amines, including clinically approved drug scaffolds. 
Late-stage C-H oxidation is a step- and atom-efficient strat-
egy to tune the efficacy and physicochemical properties of bio-
logically-active small molecule scaffolds.1 The underlying 
driver of this powerful approach is the facile and chemoselec-
tive oxidation of C-H bonds in complex molecular architectures 
by exploiting the subtle differences in C-H bond reactivity.  
This in turn enables the formation or diversification of molecu-
lar frameworks that would otherwise require the development 
of a dedicated synthetic route at an early stage in the process. 
Of the myriad of privileged heterocycles found in clinically-ap-
proved medicinal agents and natural products,2 the lactam motif 
is ubiquitous.3 From a medicinal chemistry perspective, lactams 
reduce the hydrophilicity of secondary and tertiary ammonium 
species, and provide additional hydrogen bond acceptor sites 
that could enhance drug efficacy and potentially reduce tox-
icity. Current preparative methods of lactams typically involve 
condensation of amines with a tethered carboxylic acid,4 Beck-
mann rearrangement,5 or dehydrogenative coupling of amines 
with alcohols.6 Each of these strategies involve lactam for-
mation early in the synthetic sequence, which in turn limits the 
downstream diversification of complex molecular scaffolds.  
A comparative process that involves the formation of the lac-
tam moiety by chemoselective oxidation of cyclic amines is less 
well refined, and typically requires the use of expensive and 
toxic transition metal catalysts such as osmium7a or mercury7b 
complexes and harsh oxidative conditions such as organic per-
oxides7c-e or ruthenium oxides.7f-h Recent work by Milstein et al. 
shows that catalytic oxidation of cyclic amines to the corre-
sponding lactam is indeed possible, although the efficiency of 
this process is limited by the need to heat an air-sensitive ruthe-
nium catalyst 1, to 150 °C for more than two days to effect this 
transformation (Figure 1a).8 
 
Figure 1. Lactam formation via C-H oxidation of cyclic amines. a) 
Ruthenium-catalyzed lactam formation;8 b) Iron(III)-catalyzed ox-
idation of acyclic amines;9 c) Late-stage lactam formation mediated 
by iodine oxidation of cyclic amines. 
Ferric chloride offers a cheap alternative to ruthenium cata-
lysts (Figure 1b), however substrate scope is currently limited 
 by the requirement of a strong peroxide oxidant.9 Gold nano-
particles supported on alumina do offer a mild and chemoselec-
tive route to amide and lactam formation.  However, large 
amounts of this expensive catalyst are required, which is further 
complicated by the multi-step process to prepare the colloid.10 
In contrast to the use of transition-metal catalysts, molecular io-
dine is a mild, cheap and metal-free oxidant11 that has been used 
to chemoselectively oxidize a piperidine ring found in natural 
products to the corresponding lactam in the presence of alde-
hyde, alkene, alcohol, and heteroaromatic functionalities.12 Alt-
hough there are a number of reports that describe the use of 
electrophilLFKDORJHQVRXUFHVWRFDUU\RXWĮ-oxidation of cyclic 
amines,13 these procedures to date have limited functional group 
tolerance,13a and require harsh reaction conditions.13b-e Herein, 
we report a general strategy for the chemoselective oxidation of 
a range of secondary and tertiary saturated N-heterocycles to 
IRUPȖ-į- DQGİ-lactams. To explore the selectivity of our ap-
proach, a reaction screen was undertaken using the model sub-
strate 2a. The parameters of solvent, concentration, stoichiom-
etry of iodine and iodine source were surveyed (SI, Table S1).  
Aqueous THF and aqueous DMSO were both found to be opti-
mal solvents, resulting in 91% and 90% conversion of 2a into 
3a, respectively. The stoichiometry of iodine and concentration 
of the substrate proved critical for high conversion to 3a, with 
7.5 equivalents of iodine and substrate concentration at 0.025 
M required to produce 96% of 3a. 
With optimized conditions in hand, the substrate scope of this 
reaction was explored using a range of cyclic amines 2a-r 
(Scheme 1). Our optimized conditions tolerated both electron-
rich and electron-poor benzyl-protected piperidines (2b-c) and 
tetrahydroisoquinoline 2d, with no oxidation of the exocyclic 
benzylic methylenes observed in 3a-d. Chemoselective oxida-
tion of the cyclic D-C-H bond was observed in both five-mem-
bered and seven-membered cyclic amines 2e-f, morpholine 2g, 
and piperazines 2h-i. Interestingly, stalling of the reaction was 
seen for substrate 2g, which was alleviated by using a 
DMSO/H2O solvent system instead. In contrast to benzylic sub-
strates 3a-i, concomitant lactamization and para-iodination re-
sulted in the formation of 3j from 2j. Blocking the para-position 
of the phenyl ring with a methyl group produced lactam 3k ex-
clusively. Formation of the secondary lactam 3l and sterically-
hindered 3m was also tolerated. Oxidation of the asymmetric 
piperidine 2n formed QĮ and Qȕ, isolated in a ratio of 2.7:1, 
demonstrating bias towards the sterically less-hindered product. 
Notably, no racemization of the stereogenic centers in 3m and 
3n was observed. 5HWHQWLRQRIVWHUHRFKHPLVWU\DWSRVLWLRQVȕ-to 
the nitrogen in morpholine 2o was also observed, with the trans-
orientation of the methyl groups conserved. The stereogenic 
centre in the proline-derived substrate 2p was also conserved, 
which could potentially enable access to non-natural proline de-
rivatives and proline-tagging experiments. However, no reac-
tion was observed with benzoyl-protected 2q or acyclic sub-
strate 2r. This suggests the availability of the amine lone pair 
and the conformationally-restricted ring structure is essential 
for chemoselective oxidation. 
With the substrate scope and robustness of this methodology 
established, the chemoselectivity profile was further explored 
on a suite of drug molecules (Figure 2). Lactams 5a-e were iso-
lated in moderate to excellent yields (15-92%), demonstrating 
chemoselective oxidation in the presence of alkenes, electron-
rich aromatic rings, pyridines, carboxylic acids and 
 
Scheme 1. Substrate scope of iodine-mediated oxidation of 
cyclic amines. 
 
a) Conditions: 2 (1.0 eq.), NaHCO3 (10.0 eq.), I2 (7.5 eq.) in 
THF/H2O (2.5:1, 0.025 M), RT, 4 h. b) Isolated yields shown ± 
values in parentheses show conversion to product determined by 
1H NMR analysis of the crude material against an internal standard. 
c) Reaction ran in 2.5:1 DMSO/H2O solvent system. d) % rsm = 
percentage of remaining starting material observed by crude 1H 
NMR. e) Iodine was added in three portions of 2.5 eq. each hour. 
f) Reaction stirred for 20 h. 
sulfonamides. Products 5d and 5e were isolated in low isolated? 
yields (15% and 26%, respectively), and were formed in mod-
erate conversions (56% and 57%, respectively). This is at-
tributed to formation of other oxidative by-products that were 
not isolable, in addition to their challenging purification, which 
required the use of HPLC (see SI), all of which resulted in low 
recovery of product. The morpholino-lactam 5f was also pro-
duced in 55% yield with retention of the cis-orientation of the 
ring-methyl groups. Of particular note was the regioselective 
oxidation of the asymmetrical azepane ring in 4g, forming lac-
tams JĮ and Jȕ in a ratio of 4.3:1. These results demonstrate 
the general chemoselectivity of this methodology for oxidation 
of cyclic amines in complex small molecules. 
  
Figure 2. Substrate scope of late-stage C-H oxidation of industri-
ally relevant drug scaffolds.  [a]Conditions: 4 (1.0 eq.), NaHCO3 
(10.0 eq.), I2 (7.5 eq.) in THF/H2O (2.5:1, 0.025 M), RT, 4 h.  [b]Iso-
lated yields shown ± values in parentheses show conversion to 
product determined by 1H NMR analysis of the crude material 
against an internal standard.  [c]Reaction run in 2.5:1 DMSO/H2O 
solvent system.  [d]Ratio of products determined by NMR analysis. 
When compared to other conditions reported for oxidation of 
amines directly to amides/lactams,[7h,8,9,13c] (Figure 3) the condi-
tions developed here offer substantially better chemoselective 
oxidation when applied to drugs 4h and 4i (Condition A), with 
5h isolated in high yield (83%) and 5i formed in high conver-
sion (81%).  Product 5i could only be isolated in low yield 
(30%) because further purification was required due to co-elu-
tion with an iodinated by-product during the first purification 
(see SI).  18O-labelling studies were then undertaken using 
Na18OAc as the base and H2
18O (See SI). Full 18O-incorporation 
was observed in the conversion of 2a into 18O-3a when 
H2
18O/Na18OAc was used. In contrast, only 3a was formed us-
ing H2O/Na
18OAc. This confirmed that the source of the lactam 
oxygen in the product is derived from water and not from the 
base. Additionally, 1H NMR experiments were carried out to 
further probe the mechanism of this reaction (See SI, Table S2). 
These revealed the formation of an N-iodoammonium interme-
diate upon addition of iodine (7.5 eq.) to 2a.  Dilution of the 
reaction mixture to 0.025 M with d8-THF and D2O, followed by 
the stepwise addition of sodium bicarbonate resulted in full con-
version after 2 hours and 5.0 equivalents of base. 
Taken collectively, we propose that this reaction proceeds via 
the initial formation of the charge-transfer complex 6 (Scheme 
2a).14 
Figure 3. Comparative analysis of amine oxidation conditions us-
ing drug compounds 5h and 5i as exemplars.  [a]General conditions: 
A = I2, NaHCO3, RT, 4 h; B8 = 1 (1 mol%), NaOH, 150 °C, 48 h; 
C9 = FeCl3 (5 mol%), picolinic acid (5.0 mol%), PhCO3tBu (3.0 
eq.), H2O, 50 °C, 24 h; D7h = RuO2 (10 mol%), NaIO4 (6.3 eq.), 
RT, 64 h; E13c = PhI(OAc)2 (2.2 eq.), H2O, RT, 16 h.   For detailed 
conditions see SI.  [b]Isolated yield.  [c]Complex mixture of oxida-
tive by-products observed. 
Scheme 2. a) Proposed reaction mechanism, and b) the un-
expected cyclization of Naratriptan.  
 
a) Conditions: 13 (1.0 eq.), NaHCO3 (10.0 eq.), I2 (7.5 eq.) in 
THF/H2O (2.5:1, 0.025 M), RT, 20 h. b) Isolated yield shown ± 
value in parentheses shows conversion to product determined by 
1H NMR analysis of the reaction mixture run in deuterated solvents 
against an internal standard. 
With moisture present, this would form 7, followed by slow 
formation of iminium ion 8. The observed endocyclic oxidation 
0%
20%
40%
60%
80%
100%
A B C D E
83%b
4% 0%c 0%c 0%c
81%
8%
0%c 0%c 0%c
% conversion to 5h
% conversion to 5i
A B C D E
 is most likely due to a more effective anti-periplanar E2-elimi-
nation of the N-I and C-+ĮERQGVUHODWLYHWRWKHFRQIRUPDWLRQ
ally flexible exocyclic site. The low basicity of sodium bicar-
bonate may also be responsible for the selectivity of deprotona-
tion seen for 2p, with the less sterically hindered hydrogen be-
ing deprotonated over the more acidic one.  Nucleophilic attack 
by water at the iminium carbon in 8 and subsequent deprotona-
tion forms 9. A second iodination step to form 11 via 10, ena-
bles the formation of 12 via loss of hydrogen iodide, and tau-
tomerization results in the formation of 3a. The unexpected for-
mation of product 14 in 52% conversion from the indole 13 
(Scheme 2b) further underpins the formation of the N-iodoam-
monium intermediate such as 7 on the piperidine ring, which 
can be sequestered by the proximal indole in this instance. 
In summary, we have developed a mild, late-stage strategy 
for the chemoselective oxidation of cyclic amines to the corre-
sponding lactams under mild conditions. We envisage that this 
approach could be generalized by medicinal chemists to create 
a diverse range of compounds from a small subset of molecular 
scaffolds, as well as providing synthetic access to drug metab-
olites,1e,15 potentially accelerating the hit-to-lead process of 
drug discovery compared to more traditional linear routes. 
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General experimental 
Solvents and reagents 
Unless otherwise stated: 
• Reactions were carried out under a standard atmosphere of air at room temperature, 
and glassware was not dried beforehand.  Solvents used were non-anhydrous. 
• Solvents and reagents were purchased from commercial suppliers or obtained from 
GlaxoSmithKlines internal compound storage and used as received without further 
purification.  All drug compounds used in transformations are commercially available. 
• Reactions were monitored by liquid chromatography-mass spectroscopy (LCMS) and 
Nuclear Magnetic Resonance (NMR). 
Where substrates were synthesized in-house, literature references are given for spectral data 
of these compounds. 
Chromatography 
Thin layer chromatography (TLC) was carried out using plastic-backed 50 precoated silica 
plates (particle size 0.2 mm). Spots were visualized by ultraviolet (UV) light (Ȝmax = 254 nm 
or 365 nm) and then stained with potassium permanganate solution followed by gentle 
heating.  Silica gel chromatography was carried out using the Teledyne ISCO CombiFlash
®
 
Rf+ apparatus with RediSep
®
 silica cartridges.  Reverse phase preparative HPLC was carried 
out using the Grace Reveleris
®
 Prep apparatus with an XTerra
®
 Prep RP18 OBD
TM
 column. 
Liquid chromatography mass spectrometry (LCMS) 
LCMS analysis was carried out on an H2Os Acquity UPLC instrument equipped with a BEH 
column (50 mm x 2.1 mm, 1.7 µm packing diameter) and H2Os micromass ZQ MS using 
alternate-scan positive and negative electrospray. Analytes were detected as a summed UV 
wavelength of 210  350 nm.  Two liquid phase methods were used: was a high pH method: 
Method A  High pH  40 °C, 1 mL/min flow rate. Gradient elution with the mobile 
phases as (A) 10 mM aqueous ammonium bicarbonate solution, adjusted to pH 10 
with 0.88 M aqueous ammonia and (B) acetonitrile. Gradient conditions were initially 
1% B, increasing linearly to 97% B over 1.5 min, remaining at 97% B for 0.4 min 
then increasing to 100% B over 0.1 min. 
Method B  Low pH  40 °C, 1 mL/min flow rate. Gradient elution with the mobile 
phases as (A) H2O containing 0.1% volume/volume (v/v) formic acid and (B) 
acetonitrile containing 0.1% (v/v) formic acid. Gradient conditions were initially 1% 
B, increasing linearly to 97% B over 1.5 min, remaining at 97% B for 0.4 min then 
increasing to 100% B over 0.1 min. 
Nuclear magnetic resonance (NMR) spectroscopy 
Proton (
1
H) and carbon (
13
C) spectra were recorded in deuterated solvents at ambient 
temperature using standard pulse methods on any of the following spectrometers and signal 
frequencies: Bruker AV-400 (
1
H = 400 MHz, 
13
C = 101 MHz), Bruker AV-500 (
1
H = 500 
MHz, 
13
C = 126 MHz)  and Bruker AV-600 (
1
H = 600 MHz, 
13
C = 151 MHz). Chemical 
shifts are reported in ppm and are referenced to the following solvent peaks: CDCl3 (
1
H = 
3 
 
7.27 ppm, 
13
C = 77.0 ppm), d6-DMSO (
1
H = 2.50 ppm, 
13
C = 39.5 ppm), and D2O (
1
H = 4.79 
ppm).  Where D2O was used as the solvent, the default referencing was used based on the 
D2O lock frequency for 
13
C NMR.  Peak assignments were made on the basis of chemical 
shifts, integrations, and coupling constants using COSY, DEPT, HSQC, HMBC, NOESY and 
ROESY where appropriate. Coupling constants are quoted to the nearest 0.01 Hz and 
multiplicities are described as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin), 
sextet (sxt), br. (broad) and multiplet (m). 
Infrared (IR) spectroscopy 
IR spectra were recorded using a Perkin Elmer Spectrum 1 machine. Absorption maxima 
(vmax) are reported in wavenumbers (cm
í1
). 
Mass directed automated preparation (MDAP) 
MDAP was carried out using an H2Os ZQ MS using alternate-scan positive and negative 
electrospray and a summed UV wavelength of 210350 nm. liquid phase method used was a 
high pH method: 
Xbridge C18 column (100 mm x 19 mm, 5 µm packing diameter, 20 mL/min flow 
rate) or Xbridge C18 column (150 mm x 30 mm, 5 µm packing diameter, 40 mL/min 
flow rate). Gradient elution at ambient temperature with the mobile phases as (A) 10 
mM aqueous ammonium bicarbonate solution, adjusted to pH 10 with 0.88 M 
aqueous ammonia and (B) acetonitrile. 
The elution gradients used were at a flow rate of 40 mL/min over 20 or 30 min depending on 
separation: 
Gradient A   5-30% B 
Gradient B 15-55% B 
Gradient C 30-85% B 
Gradient D 50-99% B 
Gradient E 80-99% B 
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Optimization of conditions 
Table S1: Optimization of iodine-mediated oxidation with N-benzylpiperidine 2a
[a]
 
Entry Eq. of I2 Solvent system 
Concentration of 
2a / M 
Conversion
[b]
to 3a (%) 
1 10 Toluene/H2O (2.5:1) 0.025 nr 
2 10 DCM/H2O (2.5:1) 0.025 nr 
3 10 MeOH/H2O (2.5:1) 0.025 5 
4 10 HFIP
[c]
/H2O (2.5:1) 0.025 2 
5 10 H2O 0.025 6 
6 10 MeCN/H2O (2.5:1) 0.025 6 
7 10 THF/H2O (2.5:1) 0.025 91 
8 10 DMSO/H2O (2.5:1) 0.025 90 
9 10 THF/H2O (2.5:1) 0.1
[d]
 59 
10 10 THF/H2O (2.5:1) 0.05
[d]
 57 
11 1.1 THF/H2O (2.5:1) 0.025 15 
12 2.5 THF/H2O (2.5:1) 0.025 31 
13 5.0 THF/H2O (2.5:1) 0.025 68 
14 7.5 THF/H2O (2.5:1) 0.025 96
[de]
 
15 7.5
[ef] 
THF/H2O (2.5:1) 0.025 62 
16
[fg] 
7.5 THF/H2O (2.5:1) 0.025 nr 
17 7.5 THF 0.025 nr 
18
[gh] 
7.5 THF/H2O (2.5:1) 0.025 
No change in reaction 
profile by LCMS – no 
yield gathered 
[a]
Reaction conditions: 2a (1.0 eq.), NaHCO3 (10.0 eq.), I2 (1.1  10.0 eq.) in solvent stirred at 
room temperature for 4 h; 
[b]
Conversion determined by 
1
H NMR analysis of crude material 
against an internal standard; 
[c]
HFIP = 1,1,1,3,3,3-hexafluoroisopropanol; 
[d]
At higher 
concentrations of 2a, formation of alpha -iodolactam by-products was observed; 
[de]
Isolated 
yield; 
[ef]
N-iodosuccinimide used as the iodine source instead of I2; 
[fg]
No NaHCO3 present; 
[gh]
Reaction carried out under a nitrogen atmosphere. 
  
5 
 
Mechanistic studies 
Table S2: NMR studies into mechanism of oxidation
[a] 
 
Entry Eq. NaHCO3 Time / min 
Ratio of 
2a:8:3a 
1 0.0 0 0:1:0 
2 1.0 30 0:1:0 
3 2.0 60 0:1.53:1 
4 3.0 90 0:0.56:1 
5 5.0 120 0:0:1 
6 8.0 240 0:0:1 
7 10.0 360 0:0:1 
[a]
 Reaction conditions: 2a (0.57 mmol) was added to a solution of iodine (4.28 mmol) in d
8
-
THF (2.9 mL).  This reaction mixture was stirred at RT for 1.5 h, and 
1
H NMR analysis 
showed conversion of 2a to 7.  A 1 mL aliquot of this 0.2 M solution of 7 in d
8
-THF (0.2 
mmol) was diluted to 0.025 M with d
8
-THF (4.7 mL) and D2O (2.3 mL).  Solid NaHCO3 was 
added portionwise, as described in Table S2, and the reaction mixture was monitored by 
1
H 
NMR, analyzing conversion of intermediate 7 to product 3a. 
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Figure S1: Identification of the proposed intermediate 7.  A change in the chemical shift of 
the benzylic protons of 2a was observed that was typical in difference between an amine and 
an ammonium species.
[1]
  Also no signal attributable to an iminium ion species was 
observed.
[2]
 
Spectrum 1 (blue): 2a 
Spectrum 2 (green): 7 
Spectrum 3 (grey): 3a 
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Experimental 
General procedure A 
Iodine (7.5 eq.) was added to a mixture of cyclic amine (1.0 eq.) and sodium bicarbonate 
(10.0 eq.) in THF/H2O (2.5:1, 0.025 M).  The reaction mixture was stirred gently at room 
temperature for 4 h and monitored by LCMS.  The reaction mixture was then pipetted into a 
solution of saturated aqueous sodium thiosulfate (10 mL) and saturated aqueous sodium 
bicarbonate (10 mL).  The crude material was extracted in DCM (2 x 10 mL), and the 
combined organic layers were washed with saturated aqueous sodium bicarbonate (10 mL), 
passed through a hydrophobic frit, concentrated in vacuo and then purified as described. 
General procedure B 
Iodine (7.5 eq.) was added to a mixture of cyclic amine (1.0 eq.) and sodium bicarbonate 
(10.0 eq.) in DMSO/H2O (2.5:1, 0.025 M).  The reaction mixture was stirred gently at room 
temperature for 4 h and monitored by LCMS.  The reaction mixture was then pipetted into a 
solution of saturated aqueous sodium thiosulfate (10 mL) and saturated aqueous sodium 
bicarbonate (10 mL).  The crude material was extracted in DCM (2 x 10 mL), and the 
combined organic layers were washed with saturated aqueous sodium bicarbonate (10 mL), 
passed through a hydrophobic frit, concentrated in vacuo and then purified as described. 
General procedure C 
Iodine (7.5 eq.) was added to a mixture of cyclic amine (1.0 eq.) and sodium bicarbonate 
(10.0 eq.) in THF/H2O (2.5:1, 0.025 M).  The reaction mixture was stirred gently at room 
temperature for 20 h and monitored by LCMS.  The reaction mixture was then pipetted into a 
solution of saturated aqueous sodium thiosulfate (10 mL) and saturated aqueous sodium 
bicarbonate (10 mL).  The crude material was extracted in DCM (2 x 10 mL), and the 
combined organic layers were washed with saturated aqueous sodium bicarbonate (10 mL), 
passed through a hydrophobic frit, concentrated in vacuo and then purified as described. 
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 1-(4-Methoxybenzyl)piperidine 2b
[3]
 
Piperidine (0.54 mL, 5.5 mmol), 4-methoxybenzyl chloride (0.68 mL, 5.0 mmol) and 
potassium carbonate (0.83 g, 6.0 mmol) were heated to 55 °C in MeCN (20 mL) for 42 h.  
The reaction mixture was cooled to RT, and then passed through a sintered funnel and the 
filtrate was concentrated in vacuo.  The crude material was purified by silica gel 
chromatography, with 25-80% TBME (5% methanol, 2% triethylamine 
modifier)/cyclohexane, to afford 2b (0.64 g, 63%) as a colorless oil. 
LCMS (High pH, UV, ESI) Rt = 1.11 min, [M+H]
+
 206.1 
1
H NMR (CDCl3, 400 MHz): δ 7.23 (d, J=8.6 Hz, 2H), 6.86 (d, J=8.8 Hz, 2H), 3.81 (s, 3H), 
3.42 (s, 2H), 2.37 (br. s., 4H), 1.58 (quin, J=5.6 Hz, 4H), 1.44 (br. s, 2H). 
 
 1-(4-Nitrobenzyl)piperidine 2c
[4]
 
4-nitrobenzyl bromide (1.19 g, 5.5 mmol) was slowly added to a solution of piperidine (0.49 
mL, 5.0 mmol) and DIPEA (1.31 mL, 7.5 mmol) in DCM (25 mL) at 0 °C.  After the addition 
was complete, the solution was left to stir at RT for 18 h.  The reaction mixture was then 
washed with distilled water (20 mL) and brine (20 mL), and the organic layer was passed 
through a hydrophobic frit and concentrated in vacuo.  The crude material was purified by 
silica gel chromatography with 10-45% EtOAc/cyclohexane as the eluent, to afford 2c (0.98 
g, 89%) as a yellow oil. 
LCMS (High pH, UV, ESI) Rt = 1.22 min, [M+H]
+
 221.1 
1
H NMR (CDCl3, 400 MHz): δ 8.13 (d, J=8.6 Hz, 2H), 7.48 (d, J=8.6 Hz, 2H), 3.52 (s, 2H), 
2.36 (t, J=5.3 Hz, 4H), 1.56 (quin, J=5.6 Hz, 4H), 1.41-1.46 (m, J=5.6 Hz, 2H). 
 
 2-Benzyl-1,2,3,4-tetrahydroisoquinoline 2d
[5]
 
2-picoline borane (1.05 g, 9.8 mmol) was added over 5 min to a mixture of benzaldehyde (1.0 
mL, 9.8 mmol), 1,2,3,4-tetrahydroquinoline (1.2 mL, 9.8 mmol) and acetic acid (0.3 mL) and 
the reaction mixture stirred at RT for 72 h.  The reaction was quenched with 10% aqueous 
HCl (10 mL) was added and the aqueous solution was stirred for 30 min at RT.  The solution 
was then made alkaline to pH 9 with saturated aqueous sodium bicarbonate.  The aqueous 
layer was extracted with EtOAc (2 x 30 mL), and the combined organic layers were washed 
with brine (15 mL), passed through a hydrophobic frit and concentrated in vacuo. The crude 
product was purified by silica gel chromatography with 0-50% EtOAc (1% 4M 
ammonia/methanol modifier)/cyclohexane as the eluent, to afford 2d (2.08 g, 94%) as a 
colorless oil. 
LCMS (High pH, UV, ESI) Rt = 1.32 min, [M+H]
+
 224.1 
9 
 
1
H NMR (CDCl3, 400 MHz): δ 7.50 (d, J=7.1 Hz, 2H), 7.40-7.46 (m, 2H), 7.36 (tt, J=7.1, 2.3 
Hz, 1H), 7.16-7.22 (m, 3H), 7.07 (s, 1H), 3.78 (s, 2H), 3.74 (s, 2H), 3.00 (t, J=5.8 Hz, 2H), 
2.84 (t, J=6.1 Hz, 2H). 
 
 1-Benzylazepane 2f
[6]
 
2-picoline borane (0.83 g, 8.3 mmol) was added over 5 min to a mixture of benzaldehyde 
(0.85 mL, 8.3 mmol), azepane (0.94 mL, 8.3 mmol) and acetic acid (0.3 mL) and the reaction 
mixture stirred at RT for 72 h.  The reaction was quenched with 10% aqueous HCl (10 mL) 
was added and the aqueous solution was stirred for 30 min at RT.  The solution was then 
made alkaline to pH 9 with saturated aqueous sodium bicarbonate.  The aqueous layer was 
extracted with EtOAc (2 x 30 mL), and the combined organic layers were washed with brine 
(15 mL), passed through a hydrophobic frit and concentrated in vacuo. The crude product 
was purified by reverse phase prep HPLC, with 30-85% HpH MeCN/aq. NaHCO3 as the 
eluent, to afford 2f (0.91 g, 58%) as an amber oil. 
LCMS (High pH, UV, ESI) Rt = 1.33 min, [M+H]
+
 190.2 
1
H NMR (CDCl3, 400 MHz): δ 7.41 (d, J=7.3 Hz, 2H), 7.36 (t, J=7.4 Hz, 2H), 7.28 (tt, J=7.1, 
2.5 Hz, 1H), 3.70 (s, 2H), 2.69 (br. t, J=5.2 Hz, 4H), 1.69 (br. s, 8H). 
 
 1-(p-Tolyl)piperidine 2k
[7]
 
Under a nitrogen atmosphere, 4-chlorotoluene (0.59 mL, 5.0 mmol) was added to a solution 
of piperidine (0.59 mL, 6.0 mmol), 1,3-bis(2,6-diisopropylphenyl)-1H-imidazol-3-ium 
chloride (85 mg, 0.2 mmol), potassium tert-butoxide (842 mg, 7.5 mmol) and Pd2(dba)3 (46 
mg, 0.05 mmol) in 1,4-dioxane (15 mL), and the reaction mixture was stirred at 100 °C for 24 
h.  The reaction mixture was allowed to cool to RT, before addition of water (20 mL) and 
extraction into diethyl ether (2 x 30 mL).  The combined organic layers were washed with 
brine (25 mL), passed through a hydrophobic frit and concentrated in vacuo.  The crude 
material was purified by silica gel chromatography using 0-40% (3:1 
EtOAc:EtOH)/cyclohexane as the eluent, affording 2k (363 mg, 41%) as a yellow oil. 
LCMS (High pH, UV, ESI) Rt = 1.34 min, [M+H]
+
 176.2 
1
H NMR (CDCl3, 400 MHz): δ 7.07 (d, J=8.3 Hz, 2H), 6.87 (d, J=8.6 Hz, 2H), 3.11 (t, J=5.4 
Hz, 4H), 2.28 (s, 3H), 1.73 (quin, J=5.6 Hz, 4H), 1.57 (quin, J=5.8 Hz, 2H). 
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  (R)- 1-(1-Phenylethyl)piperidine 2m
[8]
 
A solution of (R)-1-phenylethanamine (0.80 mL, 6.2 mmol) in MeCN (8.8 mL) was added to 
a mixture of 1,5-dibromopentane (1.05 mL, 7.4 mmol) and potassium carbonate (3.4 g, 24.8 
mmol) in Acetonitrile (16.0 mL).  The reaction mixture was stirred at 50 °C for 42 h.  The 
reaction mixture was allowed to cool to RT, and then filtered through a sintered funnel and 
the filtrate was concentrated in vacuo.  The crude material was purified by silica gel 
chromatography, with 35-80% TBME (5% methanol, 2% triethylamine 
modifier)/cyclohexane to afford 2m (0.95 g, 81%) as a colorless oil. 
LCMS (High pH, UV, ESI) Rt = 1.23 min, [M+H]
+
 190.1 
1
H NMR (CDCl3, 400 MHz): δ 7.31 (d, J=4.5 Hz, 4H), 7.21-7.26 (m, 1H), 3.41 (q, J=6.8 Hz, 
1H), 2.31-2.46 (m, 4H), 1.56 (quin, J=5.6 Hz, 4H), 1.41 (t, J=5.8 Hz, 2H), 1.38 (d, J=6.8 Hz, 
3H). 
 
 (S)-1-(4-Methoxybenzyl)-3-methylpiperidine 2n 
(S)-3-Methylpiperidine (0.65 mL, 5.5 mmol), 4-methoxybenzyl chloride (0.68 mL, 5.0 mmol) 
and potassium carbonate (0.83 g, 6.0 mmol) were heated to 55 °C in MeCN (20 mL) for 42 h.  
The reaction mixture was cooled to RT, and then passed through a sintered funnel and the 
filtrate was concentrated in vacuo.  The crude material was purified by silica gel 
chromatography, with 25-80% TBME (5% methanol, 2% triethylamine 
modifier)/cyclohexane, to afford 2n (0.78 g, 71%) as a colorless oil. 
LCMS (High pH, UV, ESI) Rt = 1.23 min, [M+H]
+
 220.2 
1
H NMR (CDCl3, 400 MHz): δ 7.24 (d, J=8.8 Hz, 2H), 6.86 (d, J=8.6 Hz, 2H), 3.81 (s, 3H), 
3.43 (s, 2H), 2.73-2.84 (m, 2H), 1.85 (td, J=11.1, 3.5 Hz, 1H), 1.51-1.74 (m, 5H), 0.86-0.92 
(m, 1H), 0.85 (d, J=6.3 Hz, 3H) 
13
C NMR (CDCl3, 101 MHz): δ 158.6, 130.7, 130.3, 113.5, 63.0, 61.9, 55.2, 53.9, 33.1, 31.1, 
25.6, 19.8 
Ȟmax (cm-1) (thin film): 2927, 1612, 1510 
HRMS: Calculated for C14H22NO 220.1696, found [M+H]
+
: 220.1689 (-3.4 ppm). 
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 (2R,6R)-4-(4-Methoxybenzyl)-2,6-dimethylmorpholine 2o 
(2R,6R)-2,6-Dimethylmorpholine (0.70 mL, 5.5 mmol), 4-methoxybenzyl chloride (0.68 mL, 
5.0 mmol) and potassium carbonate (0.83 g, 6.0 mmol) were heated to 50 °C in MeCN (20 
mL) for 42 h.  The reaction mixture was cooled to RT, and then passed through a sintered 
funnel and the filtrate was concentrated in vacuo.  The crude material was purified by silica 
gel chromatography, with 0-20% (3:1 EtOAc:EtOH)/cyclohexane, to afford 2o (1.03 g, 87%) 
as a colorless oil. 
LCMS (High pH, UV, ESI) Rt = 1.11 min, [M+H]
+
 236.2 
1
H NMR (CDCl3, 400 MHz): δ 7.25 (d, J=8.6 Hz, 2H), 6.86 (d, J=8.6 Hz, 2H), 4.01 (quind, 
J=6.3, 3.5 Hz, 2H), 3.80 (s, 3H), 3.42 (d, J=12.6 Hz, 1H), 3.33 (d, J=12.9 Hz, 1H), 2.45 (dd, 
J=11.0, 3.2 Hz, 2H), 2.13 (dd, J=11.0, 5.7 Hz, 2H), 1.24 (d, J=6.3 Hz, 6H) 
13
C NMR (CDCl3, 101 MHz): δ 158.7, 130.4, 129.9, 113.6, 66.7, 62.5, 58.6, 55.2, 18.2 
Ȟmax (cm-1) (thin film): 2970, 2803, 1612, 1510 
HRMS: Calculated for C14H22NO2 236.1645, found [M+H]
+
: 236.1638 (-2.9 ppm).  
 
N
  1-(1-Phenylethyl)piperidine 2s 
A solution of 1-phenylethanamine (0.80 mL, 6.2 mmol) in MeCN (8.8 mL) was added to a 
mixture of 1,5-dibromopentane (1.05 mL, 7.4 mmol) and potassium carbonate (3.4 g, 24.8 
mmol) in Acetonitrile (16.0 mL).  The reaction mixture was stirred at 50 °C for 42 h.  The 
reaction mixture was allowed to cool to RT, and then filtered through a sintered funnel and 
the filtrate was concentrated in vacuo.  The crude material was purified by silica gel 
chromatography, with 35-80% TBME (5% methanol, 2% triethylamine 
modifier)/cyclohexane to afford 2m (1.02 g, 87%) as a colorless oil. 
LCMS (High pH, UV, ESI) Rt = 1.24 min, [M+H]
+
 190.2 
1
H NMR (CDCl3, 400 MHz): δ 7.33 (d, J=4.3 Hz, 4H), 7.22-7.28 (m, 1H), 3.42 (q, J=6.8 Hz, 
1H), 2.31-2.48 (m, 4H), 1.58 (quin, J=6.3 Hz, 4H), 1.41-1.45 (m, 2H), 1.40 ppm (d, J=6.8 Hz, 
3H) 
 
  1-(4-Methoxybenzyl)-3-methylpiperidine 2t 
3-methylpiperidine (0.65 mL, 5.5 mmol), 4-methoxybenzyl chloride (0.68 mL, 5.0 mmol) 
and potassium carbonate (0.83 g, 6.0 mmol) were heated to 55 °C in MeCN (20 mL) for 21 h.  
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The reaction mixture was cooled to RT, and then passed through a sintered funnel and the 
filtrate was concentrated in vacuo.  The crude material was purified by silica gel 
chromatography, with 0-20% (3:1 EtOAc/EtOH)/cyclohexane, to afford 2p (0.87 g, 79%) as 
a colorless oil. 
LCMS (High pH, UV, ESI) Rt = 1.25 min, [M+H]
+
 220.3 
1
H NMR (CDCl3, 400 MHz): δ 7.25 (d, J=8.8 Hz, 2H), 6.87 (d, J=8.8 Hz, 2H), 3.80 (s, 3H), 
3.44 (s, 2H), 2.81 (t, J=10.7 Hz, 2H), 1.86 (td, J=11.0, 3.8 Hz, 1H), 1.53-1.75 (m, 5H), 0.88-
0.94 (m, 1H), 0.87 (d, J=6.3 Hz, 3H) 
 
 1-Benzylpiperidin-2-one 3a 
Example synthetic procedure 
Iodine (381 mg, 1.50 mmol) was added to a mixture of 1-benzylpiperidine (36.9 µL, 0.20 
mmol) and sodium bicarbonate (168 mg, 2.00 mmol) in THF/H2O (5.7/2.3 mL).  The reaction 
mixture was stirred gently at room temperature for 4 h and monitored by LCMS.  The 
reaction mixture was then pipetted into a solution of saturated aqueous sodium thiosulfate (10 
mL) and saturated aqueous sodium bicarbonate (10 mL).  The crude material was extracted in 
DCM (2 x 10 mL), and the combined organic layers were washed with saturated aqueous 
sodium bicarbonate (10 mL), passed through a hydrophobic frit, concentrated in vacuo.  The 
crude material was purified by silica gel chromatography using 35-60% TBME (with 1% 
triethylamine, 5% methanol modifier)/cyclohexane as the eluent, to afford 3a (36.3 mg, 96%) 
as a yellow oil.* 
General procedure A was followed.  Iodine (381 mg, 1.50 mmol) was added to a mixture of 
1-benzylpiperidine (36.9 µL, 0.20 mmol) and sodium bicarbonate (168 mg, 2.00 mmol) in 
THF/H2O (5.7/2.3 mL).  Purification was carried out by silica gel chromatography using 35-
60% TBME (with 1% triethylamine, 5% methanol modifier)/cyclohexane as the eluent, to 
afford 3a (36.3 mg, 96%) as a yellow oil.* 
LCMS (High pH, UV, ESI) Rt = 0.85 min, [M+H]
+
 190.1 
1
H NMR (CDCl3, 400 MHz): δ 7.23-7.36 (m, 5H), 4.61 (s, 2H), 3.21 (t, J=5.7 Hz, 2H), 2.48 
(t, J=6.5 Hz, 2H), 1.73-1.86 (m, 4H) 
13
C NMR (CDCl3, 101 MHz): δ 169.8, 137.3, 128.5, 128.0, 127.3, 50.1, 47.3, 32.5, 23.2, 21.4 
Ȟmax (cm-1) (thin film): 2944, 1632 
HRMS: Calculated for C12H16NO 190.1226, found [M+H]
+
: 190.1227 (0.5 ppm). 
*3.2 wt% iodinated lactam co-eluted with product 
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 1-(4-Methoxybenzyl)piperidin-2-one 3b 
General procedure A was followed.  Iodine (381 mg, 1.50 mmol) was added to a mixture of 
2b (41 mg, 0.20 mmol) and sodium bicarbonate (168 mg, 2.00 mmol) in THF/H2O (5.7/2.3 
mL).  Purification was carried out by silica gel chromatography using 50-100% TBME (with 
1% triethylamine & 5% methanol modifier)/cyclohexane as the eluent, to afford 3b (39.8 mg, 
91%) as a colorless oil. 
LCMS (High pH, UV, ESI) Rt = 0.85 min, [M+H]
+
 220.1 
1
H NMR (CDCl3, 400 MHz): δ 7.19 (d, J=8.6 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H), 4.52 (s, 2H), 
3.79 (s, 3H), 3.17 (t, J=5.5 Hz, 2H), 2.44 (t, J=6.5 Hz, 2H), 1.68-1.84 (m, 4H) 
13
C NMR (CDCl3, 101 MHz): δ 169.7, 158.9, 129.5, 129.5, 113.9, 55.2, 49.5, 47.0, 32.5, 
23.2, 21.4 
Ȟmax (cm-1) (thin film): 2936, 1633 
HRMS: Calculated for C13H18NO2 220.1332, found [M+H]
+
: 220.1337 (2.4 ppm). 
 
 1-(4-Nitrobenzyl)piperidin-2-one 3c 
General procedure A was followed.  Iodine (432 mg, 1.70 mmol) was added to a mixture of 
2c (50 mg, 0.23 mmol) and sodium bicarbonate (191 mg, 2.27 mmol) in THF/H2O (6.5/2.6 
mL).  Purification was carried out by silica gel chromatography using 40-60% (3:1 
EtOAc/EtOH) (with 1% ammonia modifier)/cyclohexane as the eluent, to afford 3c (50.4 mg, 
95%) as a white solid. 
LCMS (High pH, UV, ESI) Rt = 0.84 min, [M+H]
+
 235.1 
1
H NMR (CDCl3, 400 MHz): δ 8.19 (d, J=8.8 Hz, 2H), 7.43 (d, J=8.6 Hz, 2H), 4.69 (s, 2H), 
3.25 (t, J=5.4 Hz, 2H), 2.51 (t, J=6.2 Hz, 2H), 1.79-1.88 (m, 4H) 
13
C NMR (CDCl3, 101 MHz): δ 170.1, 147.4, 145.0, 128.6, 123.9, 49.9, 47.9, 32.3, 23.2, 21.3 
Ȟmax (cm-1) (thin film): 2953, 2879, 1628 
HRMS: Calculated for C12H15N2O3 235.1077, found [M+H]
+
: 235.1079 (0.6 ppm). 
 
 2-Benzyl-3,4-dihydroisoquinolin-1(2H)-one 3d 
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General procedure A was followed.  Iodine (426 mg, 1.68 mmol) was added to a mixture of 
2d (50 mg, 0.22 mmol) and sodium bicarbonate (188 mg, 2.24 mmol) in THF/H2O (6.4/2.6 
mL).  Purification was carried out by silica gel chromatography using 10-30% TBME (with 
1% 4M ammonia in methanol modifier)/cyclohexane as the eluent, to afford 3d (42.6 mg, 
80%) as a colorless oil. 
LCMS (High pH, UV, ESI) Rt = 1.09 min, [M+H]
+
 238.1 
1
H NMR (CDCl3, 400 MHz): δ 8.18 (dd, J=7.6, 1.8 Hz, 1H), 7.41-7.47 (m, 1H), 7.32-7.40 
(m, 5H), 7.27-7.32 (m, 1H), 7.18 (d, J=7.3 Hz, 1H), 4.82 (s, 2H), 3.51 (t, J=6.7 Hz, 2H), 2.96 
(t, J=6.7 Hz, 2H) 
13
C NMR (CDCl3, 126 MHz): δ 164.6, 138.1, 137.5, 131.7, 129.4, 128.7, 128.5, 128.1, 127.5, 
127.1, 126.9, 50.5, 45.4, 28.1 
Ȟmax (cm-1) (thin film): 3030, 2935, 1644 
HRMS: Calculated for C16H16NO 238.1226, found [M+H]
+
: 238.1226 (0.0 ppm). 
 
 1-Benzylpyrrolidin-2-one 3e
[9]
 
General procedure A was followed.  Iodine (295 mg, 1.16 mmol) was added to a mixture of 
1-benzylpyrrolidine (25 mg, 0.16 mmol) and sodium bicarbonate (130 mg, 1.55 mmol) in 
THF/H2O (4.4/1.8 mL).  Purification was carried out by silica gel chromatography using 30-
85% TBME (with 1% 4M ammonia in methanol modifier)/cyclohexane as the eluent, to 
afford 3e (18.7 mg, 69%) as an orange oil.* 
LCMS (High pH, UV, ESI) Rt = 0.79 min, [M+H]
+
 176.1 
1
H NMR (CDCl3, 400 MHz): δ 7.22-7.37 (m, 5H), 4.46 (s, 2H), 3.27 (t, J=7.1 Hz, 2H), 2.45 
(t, J=8.1 Hz, 2H), 2.00 (quin, J=7.6 Hz, 2H) 
13
C NMR (CDCl3, 101 MHz): δ 174.9, 136.6, 128.6, 128.1, 127.5, 46.6, 30.9, 17.7 
Ȟmax (cm-1) (thin film): 2918, 1675 
HRMS: Calculated for C11H14NO 176.1070, found [M+H]
+
: 176.1069 (-0.5 ppm). 
*LCMS shows 9% area of an unknown artifact at 0.66 min, but no impurity was observed by 
NMR, so the peak was attributed to some small amount of a highly UV active impurity. 
 
 1-Benzylazepan-2-one 3f 
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General procedure A was followed.  Iodine (503 mg, 1.98 mmol) was added to a mixture of 
2f (50 mg, 0.26 mmol) and sodium bicarbonate (222 mg, 2.64 mmol) in THF/H2O (7.6/3.0 
mL).  Purification was carried out by silica gel chromatography using 30-65% TBME (with 
1% 4M ammonia in methanol modifier)/cyclohexane as the eluent, to afford 3f (35.5 mg, 
66%) as a brown oil. 
LCMS (High pH, UV, ESI) Rt = 0.95 min, [M+H]
+
 204.1 
1
H NMR (CDCl3, 400 MHz): δ 7.22-7.35 (m, 5H), 4.59 (s, 2H), 3.24-3.35 (m, 2H), 2.57-2.64 
(m, 2H), 1.64-1.75 (m, 4H), 1.45-1.54 (m, 2H) 
13
C NMR (CDCl3, 101 MHz): δ 176.0, 137.9, 128.5, 128.1, 127.3, 51.1, 48.9, 37.2, 29.9, 
28.1, 23.4 
Ȟmax (cm-1) (thin film): 2928, 2856, 1635 
HRMS: Calculated for C13H18NO 204.1383, found [M+H]
+
: 204.1379 (-1.9 ppm). 
 
 4-Benzylmorpholin-3-one 3g 
General procedure B was followed.  Iodine (537 mg, 2.12 mmol) was added to a mixture of 
4-benzylmorpholine (48.4 µL, 0.28 mmol) and sodium bicarbonate (237 mg, 2.82 mmol) in 
DMSO/H2O (8.1/3.2 mL).  Purification was carried out by silica gel chromatography using 
30-80% TBME (with 2% triethylamine & 5% methanol modifier)/cyclohexane as the eluent, 
to afford 3g (42.0 mg, 78%) as a colorless oil.* 
LCMS (High pH, UV, ESI) Rt = 0.71 min, [M+H]
+
 192.0 
1
H NMR (CDCl3, 400 MHz): δ 7.26-7.38 (m, 5H), 4.64 (s, 2H), 4.26 (s, 2H), 3.85 (t, J=5.3 
Hz, 2H), 3.28 (t, J=5.0 Hz, 2H) 
13
C NMR (CDCl3, 101 MHz): δ 166.8, 136.1, 128.7, 128.3, 127.7, 68.2, 63.9, 49.5, 45.5 
Ȟmax (cm-1) (thin film): 2924, 2866, 1646 
HRMS: Calculated for C11H14NO2 192.1019, found [M+H]
+
: 192.1019 (-0.2 ppm). 
*LCMS shows 8% area of an unknown artifact at 0.65 min, but no impurity was observed by 
NMR, so the peak was attributed to some small amount of a highly UV active impurity. 
 
 t-Butyl 4-benzyl-3-oxopiperazine-1-carboxylate 3h 
General procedure A was followed.  Iodine (381 mg, 1.50 mmol) was added to a mixture of t-
butyl-4-benzylpiperazine-1-carboxylate (55 mg, 0.20 mmol) and sodium bicarbonate (168 
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mg, 2.00 mmol) in THF/H2O (5.7/2.3 mL).  
1
H NMR analysis of the crude material showed 
56% conversion to 3h based on the peak at 4.62 ppm, and 41% remaining starting material.  
Purification was carried out by silica gel chromatography using 0-35% TBME (with 1% 
triethylamine & 5% methanol modifier)/cyclohexane as the eluent, to afford 3h (25.6 mg, 
44%) as a white solid. 
LCMS (High pH, UV, ESI) Rt = 1.04 min, [M+H]
+
 291.1 
1
H NMR (CDCl3, 400 MHz): δ 7.24-7.38 (m, 5H), 4.63 (s, 2H), 4.17 (s, 2H), 3.59 (t, J=5.4 
Hz, 2H), 3.23-3.29 (m, 2H), 1.46 (s, 9H) 
13
C NMR (CDCl3, 101 MHz): δ 165.7, 153.8, 136.2, 128.8, 128.2, 127.8, 80.8, 50.0, 48.0, 
45.6, 40.0, 28.3 
Ȟmax (cm-1) (thin film): 2979, 2928, 1684, 1637 
HRMS: Calculated for C16H23N2O3 291.1703, found [M+H]
+
: 291.1709 (2.1 ppm). 
 
 
 4-Benzyl-1-methylpiperazin-2-one 3i 
General procedure A was followed.  Iodine (381 mg, 1.50 mmol) was added to a mixture of 
1-benzyl-4-methylpiperazine (38 mg, 0.20 mmol) and sodium bicarbonate (168 mg, 2.00 
mmol) in THF/H2O (5.7/2.3 mL).  
1
H NMR analysis of the crude material showed 45% 
conversion to 3i based on the peak at 3.54 ppm, and 29% remaining starting material against 
3,4,5-trichloropyridine (0.12 mmol) as a standard.  Purification was carried out by silica gel 
chromatography using 30-100% TBME (with 1% triethylamine & 5% methanol 
modifier)/cyclohexane as the eluent, to afford 3i (13.8 mg, 34%) as a colorless oil.* 
LCMS (High pH, UV, ESI) Rt = 0.73 min, [M+H]
+
 205.2 
1
H NMR (CDCl3, 400 MHz): δ 7.24-7.36 (m, 5H), 3.55 (s, 2H), 3.30 (t, J=5.3 Hz, 2H), 3.16 
(s, 2H), 2.95 (s, 3H), 2.67 (t, J=5.6 Hz, 2H) 
13
C NMR (CDCl3, 101 MHz): δ 167.1, 136.9, 129.0, 128.4, 127.5, 61.9, 57.4, 49.2, 48.7, 33.8 
Ȟmax (cm-1) (thin film): 2924, 2807, 1645 
HRMS: Calculated for C12H17N2O 205.1335, found [M+H]
+
: 205.1326 (-4.7 ppm). 
*LCMS shows 11% area of an unknown artifact at 0.64 min, but no impurity was observed by 
NMR, so the peak was attributed to some small amount of a highly UV active impurity. 
 
N
OI  1-(4-Iodophenyl)piperidin-2-one 3j 
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General procedure A was followed.  Iodine (381 mg, 1.50 mmol) was added to a mixture of 
1-phenylpiperidine (32.0 µL, 0.20 mmol) and sodium bicarbonate (168 mg, 2.00 mmol) in 
THF/H2O (5.7/2.3 mL).  Purification was carried out by silica gel chromatography using 40-
85% TBME (with 1% triethylamine & 5% methanol modifier)/cyclohexane as the eluent, to 
afford 3j (32.3 mg, 54%) as white crystals. 
LCMS (High pH, UV, ESI) Rt = 0.97 min, [M+H]
+
 302.0 
1
H NMR (CDCl3, 400 MHz): δ 7.70 (d, J=8.6 Hz, 2H), 7.03 (d, J=8.6 Hz, 2H), 3.62 (t, J=5.9 
Hz, 2H), 2.55 (t, J=6.0 Hz, 2H), 1.88-2.00 (m, 4H) 
13
C NMR (CDCl3, 101 MHz): δ 169.9, 143.1, 138.2, 128.1, 91.3, 51.4, 32.9, 23.5, 21.4 
Ȟmax (cm-1) (thin film): 2940, 2863, 1630 
HRMS: Calculated for C11H13INO 302.0036, found [M+H]
+
: 302.0032 (-1.4 ppm). 
 
 1-(p-Tolyl)piperidin-2-one 3k 
General procedure A was followed, except with the amendment that iodine was added to the 
reaction mixture in three portions of 2.5 equivalents after 0, 1 and 2 h.  Iodine (381 mg, 1.50 
mmol) was added in three portions to a mixture of 1-p-tolylpiperidine (35 mg, 0.20 mmol) 
and sodium bicarbonate (168 mg, 2.00 mmol) in THF/H2O (5.7/2.3 mL).  Purification was 
carried out by silica gel chromatography using 35-80% TBME (with 1% triethylamine, 5% 
methanol modifier)/cyclohexane as the eluent, to afford 3k (21.2 mg, 56%) as a white solid. 
LCMS (High pH, UV, ESI) Rt = 0.85 min, [M+H]
+
 190.1 
1
H NMR (CDCl3, 400 MHz): δ 7.20 (d, J=8.3 Hz, 2H), 7.13 (d, J=8.3 Hz, 2H), 3.59-3.65 (m, 
2H), 2.56 (t, J=5.6 Hz, 2H), 2.35 (s, 3H), 1.90-1.99 (m, 4H) 
13
C NMR (CDCl3, 101 MHz): δ 170.0, 140.9, 136.5, 129.8, 126.0, 51.8, 32.9, 23.6, 21.5, 21.0 
Ȟmax (cm-1) (thin film): 2954, 2856, 1636 
HRMS: Calculated for C12H16NO 190.1226, found [M+H]
+
: 190.1229 (1.4 ppm). 
 
 4-Phenylpiperidin-2-one 3l 
General procedure C was followed.  Iodine (590 mg, 2.33 mmol) was added to a mixture of 
4-phenylpiperidine (50 mg, 0.31 mmol) and sodium bicarbonate (260 mg, 3.10 mmol) in 
THF/H2O (8.9/3.5 mL).  
1
H NMR analysis of the crude material showed 51% conversion to 
3l based on the peak at 3.40 ppm, and 45% remaining starting material against 3,4,5-
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trichloropyridine (0.07 mmol) as a standard.  Purification was carried out by reverse phase 
chromatography with 0-60% Acetonitrile/10mM aqueous ammonium bicarbonate as the 
eluent, to afford 3l (23.6 mg, 43%) as a white solid.* 
LCMS (High pH, UV, ESI) Rt = 0.75 min, [M+H]
+
 176.1 
1
H NMR (CDCl3, 400 MHz): δ 7.36 (t, J=7.6 Hz, 2H), 7.20-7.31 (m, 3H), 6.64 (br. s., 1H), 
3.37-3.47 (m, 2H), 3.12 (tdd, J=11.1, 5.4, 2.9 Hz, 1H), 2.71 (ddd, J=17.6, 5.4, 2.0 Hz, 1H), 
2.51 (dd, J=17.9, 11.2 Hz, 1H), 2.06-2.15 (m, 1H), 1.89-2.02 (m, 1H) 
13
C NMR (CDCl3, 101 MHz): δ 172.1, 143.5, 128.8, 126.8, 126.6, 41.4, 38.7, 38.4, 29.6 
Ȟmax (cm-1) (thin film): 3286, 3193, 3029, 2872, 1651 
HRMS: Calculated for C11H14NO 176.1070, found [M+H]
+
: 176.1074  (2.5 ppm). 
*LCMS shows 6% area of an unknown artifact at 0.64 min, but no impurity was observed by 
NMR, so the peak was attributed to some small amount of a highly UV active impurity.  
 
  (R)-1-(1-Phenylethyl)piperidin-2-one 3m 
General procedure A was followed.  Iodine (381 mg, 1.50 mmol) was added to a mixture of 
2m (38 mg, 0.20 mmol) and sodium bicarbonate (168 mg, 2.00 mmol) in THF/H2O (5.7/2.3 
mL).  Purification was carried out by silica gel chromatography using 0-20% TBME (with 
1% triethylamine & 5% methanol modifier)/cyclohexane as the eluent, to afford 3m (21.6 
mg, 53%) as an amber oil.* 
LCMS (High pH, UV, ESI) Rt = 0.93 min, [M+H]
+
 204.2 
1
H NMR (CDCl3, 400 MHz): δ 7.22-7.40 (m, 5H), 6.16 (q, J=7.1 Hz, 1H), 3.11 (ddd, J=12.3, 
7.9, 4.6 Hz, 1H), 2.76-2.83 (m, 1H), 2.49 (t, J=6.7 Hz, 2H), 1.70-1.81 (m, 3H), 1.57-1.68 (m, 
1H), 1.51 (d, J=7.3 Hz, 3H) 
13
C NMR (CDCl3, 101 MHz): δ 169.6, 140.5, 128.4, 127.3, 127.2, 49.7, 41.4, 32.5, 23.2, 
21.2, 15.3 
Ȟmax (cm-1) (thin film): 2940, 2867, 1616 
HRMS: Calculated for C13H18NO 204.1383, found [M+H]
+
: 204.1382 (-0.3 ppm) 
Chiral HPLC (25 cm Chiralpak AS, 40% EtOH/n-heptane, 1.0 mL/min, detection at 215 nm) 
Rt = 3.9 min (major) and 8.0 min (minor), ee = 98.8%. 
*LCMS shows 7% area of an unknown artifact at 1.09 min, but no impurity was observed by 
NMR, so the peak was attributed to some small amount of a highly UV active impurity.  
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 (S)-1-(4-Methoxybenzyl)-5-methylpiperidin-2-one 3n
Į
 and (S)-1-(4-methoxybenzyl)-3-
methylpiperidin-2-one 3n
ȕ 
General procedure A was followed.  Iodine (381 mg, 1.50 mmol) was added to a mixture of 
2n (44 mg, 0.20 mmol) and sodium bicarbonate (168 mg, 2.00 mmol) in THF/H2O (5.7/2.3 
mL).  Purification was carried out by silica gel chromatography using 0-50% TBME (with 
1% triethylamine & 5% methanol modifier)/cyclohexane as the eluent, with 15 min 
isochratically at 40% TBME (with 1% triethylamine & 5% methanol modifier)/cyclohexane 
to afford 3n
Į
 (24.9 mg, 53%) as a colorless oil, and 3n
ȕ
 (9.5 mg, 20%) as a colorless oil. 
 
 (S)-1-(4-Methoxybenzyl)-5-methylpiperidin-2-one 3n
Į 
LCMS (High pH, UV, ESI) Rt = 0.95 min, [M+H]
+
 234.2 
1
H NMR (CDCl3, 400 MHz): δ 7.19 (d, J=8.6 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H), 4.59 (d, 
J=14.9 Hz, 1H), 4.44 (d, J=14.1 Hz, 1H), 3.79 (s, 3H), 3.15 (ddd, J=11.9, 5.1, 1.8 Hz, 1H), 
2.80 (dd, J=11.6, 10.4 Hz, 1H), 2.52 (ddd, J=17.7, 6.1, 3.3 Hz, 1H), 2.36-2.47 (m, 1H), 1.87-
1.96 (m, 1H), 1.78-1.86 (m, 1H), 1.45 (dtd, J=13.1, 11.3, 5.9 Hz, 1H), 0.94 (d, J=6.6 Hz, 3H) 
13
C NMR (CDCl3, 101 MHz): δ 169.6, 158.9, 129.4, 119.6, 113.9, 55.2, 53.9, 49.5, 31.7, 
29.5, 29.0, 18.5 
Ȟmax (cm-1) (thin film): 2928, 2837, 1634 
HRMS: Calculated for C14H20NO2 234.1489, found [M+H]
+
: 234.1492 (1.6 ppm) 
Chiral HPLC (25 cm Whelk-o 1, 10% EtOH/n-heptane, 1.0 mL/min, detection at 215 nm) Rt 
= 39.6 min, ee = 100.0%. 
 
 (S)-1-(4-Methoxybenzyl)-3-methylpiperidin-2-one 3n
ȕ 
LCMS (High pH, UV, ESI) Rt = 0.97 min, [M+H]
+
 234.2 
1
H NMR (CDCl3, 400 MHz): δ 7.19 (d, J=8.6 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H), 4.60 (d, 
J=14.4 Hz, 1H), 4.44 (d, J=14.4 Hz, 1H), 3.80 (s, 3H), 3.19 (dd, J=7.3, 5.1 Hz, 2H), 2.41-
2.52 (m, 1H), 1.91-2.00 (m, 1H), 1.78-1.89 (m, 1H), 1.65-1.78 (m, 1H), 1.52 (dtd, J=12.9, 
9.9, 3.3 Hz, 1H), 1.29 (d, J=7.1 Hz, 3H) 
13
C NMR (CDCl3, 101 MHz): δ 173.2, 158.9, 129.7, 129.4, 113.9, 55.3, 49.6, 47.4, 36.7, 
29.6, 21.7, 18.1 
Ȟmax (cm-1) (thin film): 2931, 2867, 1631 
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HRMS: Calculated for C14H20NO2 234.1489, found [M+H]
+
: 234.1495 (2.6 ppm)  
Chiral HPLC (25 cm Chiralpak AS-H, 25% EtOH/n-heptane, 1.0 mL/min, detection at 215 
nm) Rt = 5.3 min (minor) and 6.4 min (major), ee = 99.2%. 
 
 
 (2R,6R)-4-(4-Methoxybenzyl)-2,6-dimethylmorpholin-3-one 3o 
General procedure B was followed.  Iodine (381 mg, 1.50 mmol) was added to a mixture of 
2o (47 mg, 0.20 mmol) and sodium bicarbonate (168 mg, 2.00 mmol) in THF/H2O (5.7/2.3 
mL).  Purification was carried out by silica gel chromatography using 0-30% (3:1 
EtOAc/EtOH)/cyclohexane as the eluent, to afford 3o (37.5 mg, 75%) as a colorless oil. 
LCMS (High pH, UV, ESI) Rt = 0.87 min, [M+H]
+
 250.2 
1
H NMR (CDCl3, 400 MHz): δ 7.19 (d, J=8.8 Hz, 2H), 6.87 (d, J=8.6 Hz, 2H), 4.61 (d, 
J=14.4 Hz, 1H), 4.44 (d, J=14.2 Hz, 1H), 4.44 (q, J=6.9 Hz, 1H), 4.05 (sxt, J=6.3 Hz, 1H), 
3.81 (s, 3H), 3.05-3.11 (m, 2H), 1.52 (d, J=7.1 Hz, 3H), 1.18 (d, J=6.4 Hz, 3H) 
13
C NMR (CDCl3, 151 MHz): δ 169.8, 159.2, 129.6, 128.5, 114.1, 71.9, 63.7, 55.3, 51.9, 
49.1, 18.2, 17.7 
Ȟmax (cm-1) (thin film): 2977, 2934, 1645  
HRMS: Calculated for C14H20NO3 250.1438, found [M+H]
+
: 250.1429 (-3.6 ppm). 
 
 (S)-Ethyl 1-benzyl-5-oxopyrrolidine-2-carboxylate 3p
[10]
 
General procedure A was followed.  Iodine (381 mg, 1.50 mmol) was added to a mixture of 
N-benzyl-L-proline ethyl ester (44.5 µL, 0.20 mmol) and sodium bicarbonate (168 mg, 2.00 
mmol) in THF/H2O (5.7/2.3 mL).  Purification was carried out by silica gel chromatography 
using 0-50% (3:1 EtOAc/EtOH) (with 1% triethylamine modifier)/cyclohexane as the eluent, 
to afford 3p (42.4 mg, 86%) as a colorless oil. 
LCMS (Low pH, UV, ESI) Rt = 0.92 min, [M+H]
+
 248.2 
1
H NMR (CDCl3, 400 MHz): δ 7.25-7.34 (m, 3H), 7.19-7.23 (m, 2H), 5.02 (d, J=14.7 Hz, 
1H), 4.06-4.19 (m, 2H), 4.00 (d, J=14.9 Hz, 1H), 3.96 (dd, J=9.0, 3.2 Hz, 1H), 2.51-2.62 (m, 
1H), 2.41 (ddd, J=16.9, 9.5, 3.9 Hz, 1H), 2.18-2.30 (m, 1H), 2.07 (ddt, J=13.1, 9.6, 3.5 Hz, 
1H), 1.24 (t, J=7.2 Hz, 3H) 
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13
C NMR (CDCl3, 101 MHz): δ 175.0, 171.7, 135.9, 128.7, 128.5, 127.8, 61.4, 58.9, 45.6, 
29.6, 22.8, 14.1 
Ȟmax (cm-1) (thin film): 2983, 1737, 1690 
Chiral HPLC (25 cm Chiralcel OD-H, 5% EtOH/n-heptane, 1.0 mL/min, detection at 215 
nm) Rt = 11.0 min (minor) and 12.4 (major), ee = 96.2%. 
 
N
O  1-(1-Phenylethyl)piperidin-2-one 3s 
General procedure A was followed.  Iodine (381 mg, 1.50 mmol) was added to a mixture of 
2s (38 mg, 0.20 mmol) and sodium bicarbonate (168 mg, 2.00 mmol) in THF/H2O (7.5/3.0 
mL).  Purification was carried out by silica gel chromatography using 10-60% TBME (with 
5% MeOH, 1% triethylamine modifier)/cyclohexane as the eluant, but the resultant product 
was impure, so this material was re-purified by HpH MDAP (method C) to afford 3s (11.1 
mg, 27%) as an amber oil.* 
LCMS (High pH, UV, ESI) Rt = 0.94 min, [M+H]
+
 204.1 
1
H NMR (CDCl3, 400 MHz): δ 7.23-7.39 (m, 5H), 6.18 (q, J=7.1 Hz, 1H), 3.12 (ddd, J=12.3, 
8.0, 4.4 Hz, 1H), 2.76-2.86 (m, 1H), 2.50 (t, J=6.7 Hz, 2H), 1.71-1.82 (m, 3H), 1.58-1.69 (m, 
1H), 1.53 (d, J=7.1 Hz, 3H) 
*LCMS shows 13% area of an unknown artifact at 0.66 min, but no impurity was observed by 
NMR, so the peak was attributed to some small amount of a highly UV active impurity.  
 
1-(4-Methoxybenzyl)-5-methylpiperidin-2-one 3t
Į
 and 1-(4-methoxybenzyl)-3-
methylpiperidin-2-one 3t
ȕ 
General procedure A was followed.  Iodine (952 mg, 3.75 mmol) was added to a mixture of 
2t (110 mg, 0.50 mmol) and sodium bicarbonate (420 mg, 5.00 mmol) in THF/H2O (14.3/5.7 
mL).  Purification was carried out by silica gel chromatography using 0-50% TBME (with 
1% Et3N & 5% MeOH modifier)/cyclohexane as the eluant, with 15 min isochratically at 
40% TBME (with 1% triethylamine & 5% methanol modifier)/cyclohexane to afford 3t
Į
 
(21.6 mg, 19%) as a colorless oil, and 3t
ȕ
 (22.7 mg, 19%) as a colorless oil.* 
 
N
O
MeO
  1-(4-Methoxybenzyl)-5-methylpiperidin-2-one 3t
Į
 
LCMS (High pH, UV, ESI) Rt = 0.96 min, [M+H]
+
 234.1 
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1
H NMR (CDCl3, 400 MHz): δ 7.19 (d, J=8.6 Hz, 2H), 6.86 (d, J=8.6 Hz, 2H), 4.59 (d, 
J=14.4 Hz, 1H), 4.44 (d, J=14.4 Hz, 1H), 3.80 (s, 3H), 3.16 (ddd, J=12.0, 5.1, 1.9 Hz, 1H), 
2.81 (dd, J=11.9, 10.4 Hz, 1H), 2.53 (ddd, J=17.9, 5.8, 3.0 Hz, 1H), 2.42 (ddd, J=17.9, 11.4, 
6.6 Hz, 1H), 1.79-1.98 (m, 2H), 1.45 (dtd, J=13.1, 11.3, 5.9 Hz, 1H), 0.95 (d, J=6.6 Hz, 3H). 
  1-(4-methoxybenzyl)-3-methylpiperidin-2-one 3t
ȕ
 
LCMS (High pH, UV, ESI) Rt = 0.97 min, [M+H]
+
 234.1 
1
H NMR (CDCl3, 400 MHz): δ 7.19 (d, J=8.6 Hz, 2H), 6.86 (d, J=8.8 Hz, 2H), 4.60 (d, 
J=14.4 Hz, 1H), 4.44 (d, J=14.4 Hz, 1H), 3.80 (s, 3H), 3.20 (dd, J=7.3, 5.1 Hz, 2H), 2.40-
2.53 (m, 1H), 1.96 (dtd, J=12.9, 6.3, 3.3 Hz, 1H), 1.79-1.88 (m, 1H), 1.71 (dddt, J=17.2, 
10.4, 6.9, 3.4 Hz, 1H), 1.47-1.57 (m, 1H), 1.29 (d, J=7.3 Hz, 3H). 
 
*LCMS shows 13% area of an unknown artifact at 1.12 min, but no impurity was observed by 
NMR, so the peak was attributed to some small amount of a highly UV active impurity.  
 
 Ethyl 1-benzyl-5-oxopyrrolidine-2-carboxylate 3u 
General procedure A was followed.  Iodine (761 mg, 3.00 mmol) was added to a mixture of 
N-benzyl-L-proline ethyl ester (44.5 µL, 0.20 mmol), N-benzyl-D-proline ethyl ester (44.5 
µL, 0.20 mmol) and sodium bicarbonate (336 mg, 4.00 mmol) in THF/H2O (11.4/4.6 mL).  
Purification was carried out by silica gel chromatography using 0-50% (3:1 EtOAc/EtOH) 
(with 1% triethylamine modifier)/cyclohexane as the eluent, to afford 3u (54.7 mg, 55%) as a 
colorless oil. 
LCMS (Low pH, UV, ESI) Rt = 0.92 min, [M+H]
+
 248.2 
1
H NMR (CDCl3, 400 MHz): δ 7.27-7.36 (m, 3H), 7.20-7.24 (m, 2H), 5.03 (d, J=14.7 Hz, 
1H), 4.08-4.21 (m, 2H), 4.01 (d, J=14.9 Hz, 1H), 3.97 (dd, J=9.0, 3.2 Hz, 1H), 2.53-2.63 (m, 
1H), 2.42 (ddd, J=16.9, 9.5, 3.7 Hz, 1H), 2.19-2.31 (m, 1H), 2.08 (ddt, J=13.1, 9.6, 3.5 Hz, 
1H), 1.25 (t, J=7.1 Hz, 3H). 
 
 Oxo-risperidone 5a 
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General procedure B was followed.  Iodine (190 mg, 0.75 mmol) was added to a mixture of 
rispoeridone (41 mg, 0.10 mmol) and sodium bicarbonate (84 mg, 1.00 mmol) in THF/H2O 
(2.9/1.1 mL).  Purification was carried out by high pH MDAP (Method B), to afford 5a (24.1 
mg, 57%) as a pale brown solid. 
LCMS (High pH, UV, ESI) Rt = 0.88 min, [M+H]
+
 425.3 
1
H NMR (DMSO-d6, 400 MHz): δ 8.06 (dd, J=8.7, 5.3 Hz, 1H), 7.70 (dd, J=9.3, 2.2 Hz, 1H), 
7.30 (td, J=9.0, 2.2 Hz, 1H), 3.76-3.81 (m, 2H), 3.69-3.76 (m, 1H), 3.46-3.55 (m, 1H), 3.33-
3.42 (m, 3H), 2.76 (t, J=6.6 Hz, 2H), 2.70 (dd, J=5.7, 1.3 Hz, 1H), 2.62-2.68 (m, 2H), 2.55-
2.62 (m, 1H), 2.26-2.34 (m, 1H), 2.23 (s, 3H), 2.02-2.13 (m, 1H), 1.81-1.89 (m, 2H), 1.72-
1.80 (m, 2H) 
13
C NMR (DMSO-d6, 126 MHz): δ 167.2, 163.6 (d, J=13.9 Hz), 163.2, 163.0, 161.2 (d, 
J=231.2 Hz), 158.8, 158.8, 156.9, 124.3 (d, J=12.0 Hz), 117.4 (d, J=3.7 Hz), 113.1 (d, J=25.0 
Hz), 97.9 (d, J=27.7 Hz), 46.6, 45.4, 42.6, 36.1, 31.2, 30.8, 27.5, 24.0, 21.8, 21.3, 19.0 
Ȟmax (cm-1) (thin film): 3060, 2959, 1658, 1635 
HRMS: Calculated for C23H26F N4O3 425.1983, found [M+H]
+
: 425.1977 (-1.6 ppm). 
 
 Oxo-varenicline 5b 
General procedure A was followed.  Iodine (190 mg, 0.75 mmol) was added to a mixture of 
varenicline hydrochloride (25 mg, 0.10 mmol) and sodium bicarbonate (84 mg, 1.00 mmol) 
in THF/H2O (2.9/1.1 mL).  Purification was carried out by reverse phase flash 
chromatography using 0-30% Acetonitrile/10 mM aqueous ammonium bicarbonate to afford 
5b (11.9 mg, 53%) as a white solid. 
LCMS (High pH, UV, ESI) Rt = 0.56 min, [M+H]
+
 226.2 
1
H NMR (CDCl3, 400 MHz): δ 8.81 (dd, J=9.3, 2.0 Hz, 2H), 8.04 (d, J=13.0 Hz, 2H), 5.14 
(br. s., 1H), 3.91 (d, J=3.9 Hz, 1H), 3.84 (ddd, J=11.1, 4.3, 1.2 Hz, 1H), 3.72 (t, J=4.3 Hz, 
1H), 3.37 (ddt, J=11.1, 2.4, 1.0 Hz, 1H), 2.59-2.66 (m, 1H), 2.51 (d, J=11.5 Hz, 1H) 
13
C NMR (CDCl3, 101 MHz): δ 171.9, 147.8, 146.8, 144.5, 144.3, 143.5, 143.3, 123.1, 122.6, 
49.2, 48.2, 38.9, 37.7 
Ȟmax (cm-1) (thin film): 3196, 2969, 1657 
HRMS: Calculated for C13H12N3O 226.0975, found [M+H]
+
: 226.0977 (0.8 ppm). 
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 Oxo-nafoxidine 5c 
General procedure A was followed.  Iodine (95 mg, 0.38 mmol) was added to a mixture of 
nafoxidine hydrochloride (23 mg, 0.05 mmol) and sodium bicarbonate (42 mg, 0.50 mmol) in 
THF/H2O (1.4/0.6 mL).  Purification was carried out by silica gel chromatography using 10-
45% EtOAc/cyclohexane as the eluent, to afford 5c (20.2 mg, 92%) as a white solid.* 
LCMS (High pH, UV, ESI) Rt = 1.42 min, [M+H]
+
 440.2 
1
H NMR (CDCl3, 400 MHz): δ 7.09-7.14 (m, 2H), 7.00-7.07 (m, 3H), 6.97 (d, J=8.8 Hz, 2H), 
6.70-6.80 (m, 4H), 6.60 (dd, J=8.6, 2.8 Hz, 1H), 4.09 (t, J=5.2 Hz, 2H), 3.81 (s, 3H), 3.67 (t, 
J=5.2 Hz, 2H), 3.59 (t, J=7.1 Hz, 2H), 2.95 (dd, J=8.6, 7.1 Hz, 2H), 2.78 (dd, J=8.6, 6.3 Hz, 
2H), 2.40 (t, J=8.1 Hz, 2H), 2.03 (quin, J=7.6 Hz, 2H) 
13
C NMR (CDCl3, 101 MHz): δ 175.3, 158.5, 157.0, 143.3, 137.7, 134.6, 134.5, 132.6, 132.2, 
130.4, 128.3, 127.6, 127.4, 125.7, 113.9, 113.2, 110.8, 66.5, 55.3, 49.0, 42.5, 30.8, 30.8, 29.0, 
18.2 
Ȟmax (cm-1) (thin film): 2930, 2833, 1681 
HRMS: Calculated for C29H30NO3 440.2220, found [M+H]
+
: 440.2219 (-0.4 ppm). 
*
1
H NMR analysis showed presence of 4wt% of an oxidized product – likely to arise from 
aromatization of the fused cyclohexene ring 
 
 Oxo-acrivastine 5d 
General procedure A was followed.  Iodine (190 mg, 0.75 mmol) was added to a mixture of 
acrivastine (35 mg, 0.10 mmol) and sodium bicarbonate (84 mg, 1.00 mmol) in THF/H2O 
(2.9/1.1 mL).  
1
H NMR analysis of the crude material showed 56% conversion to 5d based on 
the peak at 2.21 ppm against hexamethyldisiloxane (24.0 µmol) as a standard.  Purification 
was carried out by reverse phase preparative HPLC using 15-55% MeCN (with 0.1% 
ammonia modifier)/10 mM aqueous ammonium bicarbonate as the eluent, to afford 5d (5.6 
mg, 15%) as a brown solid.* 
LCMS (High pH, UV, ESI) Rt = 0.74 min, [M+H]
+
 363.2 
1
H NMR (DMSO-d6, 400 MHz): δ 7.74 (t, J=7.6 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.57 (d, 
J=15.7 Hz, 1H), 7.29 (d, J=8.1 Hz, 2H), 7.14 (d, J=8.1 Hz, 2H), 6.91 (d, J=7.6 Hz, 1H), 6.83 
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(d, J=15.7 Hz, 1H), 6.78 (t, J=6.9 Hz, 1H), 3.85 (d, J=7.1 Hz, 2H), 3.30 (t, J=7.1 Hz, 3H), 
2.38 (s, 3H), 2.21 (t, J=8.1 Hz, 2H), 1.91 (quin, J=7.5 Hz, 2H) 
13
C NMR (DMSO-d6, 126 MHz): δ 174.1, 167.6[a] 157.4, 152.3, 143.3, 142.7, 138.3, 137.3, 
134.5, 129.8, 129.7, 127.9, 123.3, 122.9, 55.4, 46.8, 41.5, 30.7, 21.3, 17.8  
[a]
Peak not seen in 1D 
13
C spectrum, coupling seen to this chemical shift in HMBC. 
Ȟmax (cm-1) (thin film): 3380 (br), 2923, 1678, 1643 
HRMS: Calculated for C22H23N2O3 363.1703, found [M+H]
+
: 363.1703 (-0.1 ppm). 
*LCMS shows 7% area of an unknown artifact at 0.73 min, but no impurity was observed by 
NMR, so the peak was attributed to some small amount of a highly UV active impurity. 
 
 Oxo-vardenafil 5e 
General procedure B was followed.  Iodine (190 mg, 0.75 mmol) was added to a mixture of 
vardenafil hydrochloride trihydrate (58 mg, 0.10 mmol) and sodium bicarbonate (84 mg, 1.00 
mmol) in THF/H2O (2.9/1.1 mL).  
1
H NMR analysis of the crude material showed 57% 
conversion to 5e based on the peak at 3.66 ppm against hexamethyldisiloxane (24.0 µmol) as 
a standard.  Purification was carried out by high pH MDAP (Method C), to afford 5e (13.2 
mg, 26%) as a white solid. 
LCMS (High pH, UV, ESI) Rt = 0.93 min, [M+H]
+
 503.3 
1
H NMR (CDCl3, 400 MHz): δ 9.70 (br. s., 1H), 8.48 (d, J=2.4 Hz, 1H), 7.92 (dd, J=8.8, 2.4 
Hz, 1H), 7.19 (d, J=8.8 Hz, 1H), 4.35 (q, J=6.9 Hz, 2H), 3.72 (s, 2H), 3.34-3.47 (m, 6H), 
3.01 (t, J=7.6 Hz, 2H), 2.64 (s, 3H), 1.89 (dq, J=14.9, 7.5 Hz, 2H), 1.60 (t, J=7.0 Hz, 3H), 
1.09 (t, J=7.2 Hz, 3H), 1.04 (t, J=7.3 Hz, 3H) 
 
13
C NMR (CDCl3, 101 MHz): δ 163.1, 160.3, 154.5, 146.5, 144.3, 140.4, 132.5, 130.3, 128.4, 
119.1, 113.6, 113.4, 66.2, 48.8, 45.5, 43.1, 41.7, 27.9, 20.9, 14.5, 14.4, 14.0, 12.0 
Ȟmax (cm-1) (thin film): 3533 (br), 3325, 2968, 1697, 1641 
HRMS: Calculated for C23H31N6O5S 503.2071, found [M+H]
+
: 503.2073 (0.3 ppm). 
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 Oxo-fenpropimorph (diastereomeric mixture) 5f 
General procedure B was followed.  Iodine (190 mg, 0.75 mmol) was added to a mixture of 
fenpropimorph (30 mg, 0.10 mmol) and sodium bicarbonate (84 mg, 1.00 mmol) in THF/H2O 
(2.9/1.1 mL).  Purification was carried out by silica gel chromatography using 0-25% TBME 
(with 1% triethylamine & 5% methanol modifier)/cyclohexane as the eluent, to afford 5f 
(17.6 mg, 55%) (dr 1.2:1) as a colorless oil. 
LCMS (High pH, UV, ESI) Rt = 1.38 min, [M+H]
+
 318.3 
1
H NMR (CDCl3, 400 MHz): δ 7.30 (dd, J=8.4, 2.3 Hz, 4H), 7.09 (d, J=8.3 Hz, 4H), 4.20 (q, 
J=6.8 Hz, 1H), 4.13 (q, J=6.8 Hz, 1H), 3.76-3.85 (m, 1H), 3.58-3.67 (m, 1H), 3.14-3.41 (m, 
6H), 3.07 (dd, J=12.0, 2.7 Hz, 1H), 2.99 (dd, J=11.7, 2.7 Hz, 1H), 2.56-2.66 (m, 2H), 2.44-
2.52 (m, J=7.3 Hz, 1H), 2.39 (dd, J=13.7, 8.6 Hz, 1H), 2.18 (dq, J=14.9, 7.6 Hz, 2H), 1.45 
(dd, J=6.8, 2.4 Hz, 6H), 1.32 (s, 18H), 1.23 (dd, J=15.4, 6.1 Hz, 6H), 0.89 (t, J=7.0 Hz, 6H) 
13
C NMR (CDCl3, 151 MHz): δ 170.0, 169.9, 148.8, 148.7, 137.3, 137.2, 128.6, 128.5, 125.1, 
125.1, 74.2, 74.2, 68.9, 68.6, 53.8, 53.4, 52.7, 52.3, 40.8, 40.3, 34.3, 32.9, 32.6, 31.4, 18.5, 
18.4, 18.4, 18.3, 17.6, 17.5 
Ȟmax (cm-1) (thin film): 2962, 2870, 1652 
HRMS: Calculated for C20H32NO2 318.2428, found [M+H]
+
: 318.2429 (0.5 ppm). 
 
7-Oxo-azelastine 5g
Į
 and 2-oxo-azelastine 5g
ȕ
 
General procedure A was followed.  Iodine (190 mg, 0.75 mmol) was added to a mixture of 
azelastine hydrochloride (42 mg, 0.10 mmol) and sodium bicarbonate (84 mg, 1.00 mmol) in 
THF/H2O (2.9/1.1 mL).  Purification was carried out by silica gel chromatography using 0-
25% (3:1 EtOAc/EtOH, with 1% triethylamine modifier)/cyclohexane as the eluent, to afford 
a co-eluting mixture of 5g
Į
 and 5g
ȕ
 (26.9 mg, 68%*), in 4.3:1 ratio of 5g
Į
: 5g
ȕ
, determined 
by 
1
H NMR.  The isomers were only separable by high pH MDAP (Method C) to afford 5g
Į
 
(14.8 mg, 37%) as a white solid and 5g
ȕ
 (2.2 mg, 6%) as a white solid. 
*Based on 30.6 mg isolated yield, with 12.1 wt% cyclohexane impurity by 
1
H NMR. 
 
 7-Oxo-azelastine 5g
Į
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LCMS (High pH, UV, ESI) Rt = 1.10 min, [M+H]
+
 396.2 
1
H NMR (CDCl3, 400 MHz): δ 8.44-8.52 (m, 1H), 7.66-7.77 (m, 3H), 7.26-7.30 (m, 2H), 
7.19 (d, J=8.3 Hz, 2H), 5.27 (tt, J=11.4, 4.4 Hz, 1H), 4.27 (s, 2H), 3.76 (dd, J=15.7, 10.3 Hz, 
1H), 3.33 (ddd, J=15.5, 6.2, 1.3 Hz, 1H), 3.08 (s, 3H), 2.64-2.78 (m, 2H), 2.11-2.25 (m, 2H), 
2.02-2.11 ppm (m, 2H) 
13
C NMR (CDCl3, 151 MHz): δ 174.7, 158.5, 144.8, 136.2, 133.0, 132.7, 131.3, 129.8, 128.9, 
128.6, 128.1, 127.6, 124.7, 57.3, 48.5, 38.3, 35.8, 33.8, 32.4, 28.1 
Ȟmax (cm-1) (thin film): 2939, 1635 
HRMS: Calculated for C22H23ClN3O2 396.1473, found [M+H]
+
: 396.1485 (3.0 ppm). 
2-Oxo-azelastine 5g
ȕ
 
LCMS (High pH, UV, ESI) Rt = 1.16 min, [M+H]
+
 396.2 
1
H NMR (CDCl3, 400 MHz): δ 8.43-8.49 (m, 1H), 7.69-7.74 (m, 2H), 7.64-7.69 (m, 1H), 
7.28 (d, J=8.6 Hz, 2H), 7.19 (d, J=8.6 Hz, 2H), 5.22-5.31 (m, 1H), 4.26 (s, 2H), 3.66 (dd, 
J=14.9, 10.3 Hz, 1H), 3.26-3.37 (m, 2H), 3.05 (s, 3H), 2.76 (dt, J=13.8, 1.9 Hz, 1H), 2.15-
2.23 (m, 1H), 1.95-2.11 (m, 2H), 1.74-1.87 (m, 1H) 
13
C NMR (CDCl3, 101 MHz): δ 172.4, 158.2, 144.6, 136.2, 132.9, 132.6, 131.3, 129.8, 128.8, 
128.6, 128.2, 127.6, 124.7, 52.3, 50.7, 42.6, 38.4, 36.0, 34.9, 26.2 
Ȟmax (cm-1) (thin film): 2926, 1646 
HRMS: Calculated for C22H23ClN3O2 39.1473, found [M+H]
+
: 396.1475 (0.3 ppm). 
 
 Oxo-melperone 5h 
General procedure A was followed.  Iodine (190 mg, 0.75 mmol) was added to a mixture of 
melperone hydrochloride (30 mg, 0.10 mmol) and sodium bicarbonate (84 mg, 1.00 mmol) in 
THF/H2O (2.9/1.1 mL).  Purification was carried out by silica gel chromatography using 0-
60% TBME (with 1% triethylamine, 5% methanol modifier)/cyclohexane as the eluent, to 
afford 5h (23.0 mg, 83%) as a white solid. 
LCMS (High pH, UV, ESI) Rt = 1.00 min, [M+H]
+
 278.2 
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1
H NMR (CDCl3, 400 MHz): δ 7.97 (dd, J=9.0, 5.4 Hz, 2H), 7.11 (t, J=8.6 Hz, 2H), 3.47-
3.55 (m, 1H), 3.36-3.44 (m, 1H), 3.32 (d, J=4.0 Hz, 1H), 3.29-3.31 (m, 1H), 2.97 (t, J=7.1 
Hz, 2H), 2.40 (dtd, J=11.9, 10.1, 1.8 Hz, 1H), 1.99 (quind, J=7.1, 1.8 Hz, 2H), 1.81-1.93 (m, 
3H), 1.36-1.48 (m, 1H), 0.97 (d, J=6.3 Hz, 3H) 
13
C NMR (CDCl3, 101 MHz): δ 198.0, 169.7, 165.7 (d, J=258.0 Hz), 133.3 (d, J=3.2 Hz), 
130.7 (d, J=9.6 Hz), 115.6 (d, J=22.4 Hz), 46.8, 46.0, 40.5, 35.6, 31.0, 27.9, 21.5, 21.0 
Ȟmax (cm-1) (thin film): 2950, 2869, 1684, 1627 
HRMS: Calculated for C16H21FNO2 278.1551, found [M+H]
+
: 278.1553 (0.7 ppm). 
 
Oxo-bepridil 5i and oxo-iodo-bepridil 15 
General procedure A was followed.  Iodine (190 mg, 0.75 mmol) was added to a mixture of 
bepridil hydrochloride hydrate (42 mg, 0.10 mmol) and sodium bicarbonate (84 mg, 1.00 
mmol) in THF/H2O (2.9/1.1 mL).  
1
H NMR analysis of the crude material showed 81% 
conversion to 5i and 17% conversion to 15 based on peaks at 6.85 and 6.63 ppm, 
respectively, against hexamethyldisiloxane (24.0 µmol) as a standard.  Purification was 
attempted initially by silica gel chromatography using 0-50% EtOAc (with 1% 4M ammonia 
in methanol modifier)/cyclohexane, but the products 5i and 15 co-eluted.  Separation could 
only be achieved by high pH MDAP (Method E), to afford 5i (11.5 mg, 30%) as a yellow oil, 
and 15 (2.6 mg, 5%) as a yellow oil. 
 
N
N
O
O
 Oxo-bepridil 5i 
LCMS (High pH, UV, ESI) Rt = 1.40 min, [M+H]
+
 381.3 
1
H NMR (CDCl3, 400 MHz): δ 7.29 (t, J=6.8 Hz, 2H), 7.15-7.24 (m, 5H), 6.84 (d, J=8.3 Hz, 
2H), 6.71 (t, J=7.2 Hz, 1H), 4.66 (d, J=16.7 Hz, 1H), 4.49-4.58 (m, 2H), 3.66 (dd, J=7.2, 2.9 
Hz, 2H), 3.61 (q, J=5.1 Hz, 1H), 3.52 (dd, J=10.1, 4.0 Hz, 1H), 3.40-3.47 (m, 1H), 3.34 (td, 
J=9.0, 5.2 Hz, 1H), 3.11-3.20 (m, 2H), 2.15-2.34 (m, 2H), 1.80-1.93 (m, 2H), 1.66-1.77 (m, 
1H), 0.91 (dd, J=6.7, 0.9 Hz, 6H) 
13
C NMR (CDCl3, 101 MHz): δ 175.4, 148.6, 138.5, 129.2, 128.5, 126.8, 126.7, 117.1, 113.4, 
78.0, 69.8, 54.1, 49.9, 49.6, 45.6, 31.1, 28.6, 19.4, 18.4 
Ȟmax (cm-1) (thin film): 2957, 2872, 1679 
HRMS: Calculated for C24H33N2O2 381.2537, found [M+H]
+
: 381.2538 (0.4 ppm). 
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 Oxo-iodo-bepridil 15 
LCMS (High pH, UV, ESI) Rt = 1.53 min, [M+H]
+
 507.1* 
1
H NMR (CDCl3, 400 MHz): δ 7.43 (d, J=9.1 Hz, 2H), 7.29 (t, J=7.6 Hz, 2H), 7.23 (t, J=7.1 
Hz, 1H), 7.16 (d, J=7.1 Hz, 2H), 6.63 (d, J=9.1 Hz, 2H), 4.62 (d, J=17.2 Hz, 1H), 4.51 (d, 
J=16.9 Hz, 1H), 4.44-4.49 (m, 1H), 3.64 (d, J=7.1 Hz, 2H), 3.59 (dd, J=10.1, 5.3 Hz, 1H), 
3.51 (dd, J=10.1, 4.0 Hz, 1H), 3.31-3.47 (m, 2H), 3.12-3.20 (m, 2H), 2.16-2.34 (m, 2H), 
1.81-1.94 (m, 2H), 1.70-1.80 (m, 1H), 0.91 (d, J=6.8 Hz, 6H) 
13
C NMR (CDCl3, 126 MHz): δ 175.4, 147.9, 137.9, 137.8, 128.6, 127.0, 126.7, 115.6, 110.0, 
78.0, 69.6, 54.1, 49.8, 49.7, 45.7, 31.0, 28.6, 19.4, 18.4 
Ȟmax (cm-1) (thin film): 2956, 2870, 1677 
HRMS: Calculated for C24H32IN2O2 507.1503, found [M+H]
+
: 507.1518 (3.0 ppm). 
*LCMS analysis shows 12% area of an unknown impurity with a mass loss of 90 relative to 
15 – possibly resulting from some debenzylation of 15 formed in LCMS.  No impurity 
observed in NMR, so likely instability in LCMS. 
 
  1-Methyl-5'-(2-(N-methylsulfamoyl)ethyl)-2'-oxo-1-azaspiro 
[bicyclo[2.2.1]heptane-7,3'-indolin]-1-ium iodide 14 
General procedure C was followed.  Iodine (190 mg, 0.75 mmol) was added to a mixture of 
naratriptan hydrochloride (37 mg, 0.10 mmol) and sodium bicarbonate (84 mg, 1.00 mmol) in 
THF/H2O (2.9/1.1 mL).  
1
H NMR analysis of a 0.6 mL aliquot from a reaction mixture using 
d
8
-THF/D2O as the solvent system showed 52% conversion to 14 based on the peak at 2.64 
ppm against hexamethyldisiloxane (9.4 µmol) as a standard.  Purification was carried out by 
reverse phase preparative HPLC using 0-25% MeCN (with 0.1% ammonia modifier)/10 mM 
aqueous ammonium bicarbonate as the eluent, to afford 14 (11.5 mg, 24%) as a white solid. 
LCMS (High pH, UV, ESI) Rt = 0.52 min, [M]
+
 350.1 
1
H NMR (D2O, 500 MHz): δ 7.34 (d, J=8.0 Hz, 2H), 6.98 (d, J=8.2 Hz, 1H), 4.38 (tt, J=11.3, 
4.4 Hz, 1H), 3.91 (tt, J=11.5, 4.7 Hz, 1H), 3.72-3.80 (m, 1H), 3.66 (ddd, J=10.8, 9.1, 5.1 Hz, 
1H), 3.46 (td, J=7.6, 1.8 Hz, 2H), 3.07 (t, J=7.7 Hz, 2H), 3.01 (ddt, J=11.8, 8.0, 3.8 Hz, 1H), 
2.89-2.94 (m, 1H), 2.82-2.89 (m, 1H), 2.76 (s, 3H), 2.69 (s, 3H), 2.12 (ddd, J=13.4, 8.4, 5.1 
Hz, 1H), 1.91 (ddd, J=12.9, 8.0, 4.3 Hz, 1H)* 
30 
 
13
C NMR (D2O, 101 MHz): δ 188.5, 136.1, 135.5, 131.4, 121.4, 115.3, 85.5, 66.0, 65.9, 53.9, 
45.1, 43.0, 41.6, 31.6, 31.3, 31.1, 29.7 
Ȟmax (cm-1) (thin film): 3500-3000 (br), 2973, 1718, 1641 
HRMS: Calculated for C17H24N3O3S 350.1533, found [M]
+
: 350.1537 (1.3 ppm). 
*N-H signals not observed in D2O 
 
 
Isotopic-labeling experiments 
 
 
18
O-1-Benzylpiperidin-2-one 
18
O-3a 
General procedure A was followed.  Iodine (190 mg, 0.75 mmol) was added to a mixture of 
1-benzylpiperidine (18.5 µL, 0.10 mmol) and sodium bicarbonate (84 mg, 1.00 mmol) in 
THF/H2
18
O (2.9/1.1 mL).  Purification was carried out by silica gel chromatography using 
30-85% TBME (with 1% 4M ammonia in methanol modifier)/cyclohexane as the eluent, to 
afford 
18
O-3a (19.2 mg, 100%) as a yellow oil.* 
LCMS (High pH, UV, ESI) Rt = 0.86 min, [M+H]
+
 192.2 (100%), 190.2 (3%) 
1
H NMR (CDCl3, 400 MHz): δ 7.30-7.36 (m, 2H), 7.24-7.30 (m, 3H), 4.61 (s, 2H), 3.21 (t, 
J=6.0 Hz, 2H), 2.48 (t, J=6.5 Hz, 2H), 1.73-1.85 (m, 4H) 
HRMS: Calculated for C12H16N
18
O 192.1269, found [M+H]
+
: 192.1266 (-1.6 ppm). 
*LCMS and 
1
H NMR analysis showed presence of 7% of an iodinated lactam by-product, 
which could not be separated 
 
Studies with sodium acetate: general procedure A was followed for all cases, although the 
reaction mixtures were not purified. 
• with NaOAc/H2O 
Iodine (381 mg, 1.50 mmol) was added to a mixture of 1-benzylpiperidine (36.9 µL, 0.20 
mmol) and sodium acetate (164 mg, 2.00 mmol) in THF/H2O (5.7/2.3 mL). 
LCMS (High pH, UV, ESI) Rt = 0.86 min (3a), [M+H]
+
 190.1 (100%). 
• with Na
18
OAc/H2O 
Iodine (381 mg, 1.50 mmol) was added to a mixture of 1-benzylpiperidine (36.9 µL, 0.20 
mmol) and sodium acetate (164 mg, 2.00 mmol) in THF/H2O (5.7/2.3 mL). 
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LCMS (High pH, UV, ESI) Rt = 0.85 min (3a), [M+H]
+
 190.1 (100%). 
• with Na
18
OAc/H2
18
O 
Iodine (381 mg, 1.50 mmol) was added to a mixture of 1-benzylpiperidine (36.9 µL, 0.20 
mmol) and sodium acetate (164 mg, 2.00 mmol) in THF/H2O (5.7/2.3 mL). 
LCMS (High pH, UV, ESI) Rt = 0.86 min (3a), [M+H]
+
 192.1 (100%). 
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Investigating late-stage oxidation under Milstein conditions
[11]
 
Stock solutions of Acridine Ru complex 1 (6 mg, 0.01 mmol) in 1,4-dioxane (1.5 mL) and 
NaOH (40 mg, 1.01 mmol) in water (1.5 mL) were prepared.  1.0 extra equivalent of NaOH 
was added compared to the literature conditions in order to neutralize the HCl salt of the drug 
substrates.  A 0.15 mL aliquot of the catalyst solution and a 0.15 mL aliquot of the NaOH 
solution were added to either melperone hydrochloride (30 mg, 0.10 mmol) or bepridil 
hydrochloride hydrate (42 mg, 0.10 mmol).  The reaction mixture was heated to 150 °C for 
48 h.  The reaction mixture was then allowed to cool to room temperature, before diluting in 
water (1 mL) and extracting into DCM (2 x 1.5 mL).  The crude solution was concentrated 
under flow of nitrogen, and the crude material was redissolved in CDCl3 and analyzed by 
1
H 
NMR. 
1
H NMR analysis of the crude materials showed: 
• 4% conversion to 5h and 93% remaining starting material based on peaks at 3.40 ppm 
and 7.10 ppm, respectively, against 3,4,5-trichloropyridine (0.086 mmol) as a 
standard; 
• 8% conversion to 5i and 91% remaining starting material based on peaks at 2.24 ppm 
and 6.79 ppm, respectively, against 3,4,5-trichloropyridine (0.119 mmol) as a 
standard. 
 
Investigating late-stage oxidation under Emmert conditions
[12]
 
A stock solution of FeCl3.6H2O (14 mg, 0.05 mmol) in pyridine (3.60 mL) was prepared.  A 
0.36 mL aliquot of this solution was added to a mixture of 2-picolinic acid (0.6 mg, 5.0 
µmol), tert-butyl benzoperoxoate (57.0 µL, 0.30 mmol), water (16.2 µL, 0.90 mmol), and 
either melperone hydrochloride (30 mg, 0.10 mmol) or bepridil hydrochloride hydrate (42 
mg, 0.10 mmol), and the reaction mixture was stirred at 50 °C for 24 h.  The solvent was 
removed and the crude residue was redissolved in CDCl3 and analyzed by 
1
H NMR. 
1
H NMR analysis of the crude materials showed: 
• 0% conversion to 5h against 3,4,5-trichloropyridine (0.056 mmol) as a standard; 
• 0% conversion to 5i against 3,4,5-trichloropyridine (0.094 mmol) as a standard. 
 
Investigating late-stage oxidation under classical RuIVO2/NaIO4 conditions
[13]
 
Either melperone hydrochloride (30 mg, 0.10 mmol) or bepridil hydrochloride hydrate (42 
mg, 0.10 mmol) was added to a mixture of ruthenium(IV) oxide (1.3 mg, 10.0 µmol) and 
sodium periodate (135.0 mg, 0.63 mmol) in ethyl acetate (0.24 mL) and water (0.94 mL), and 
the reaction mixture was stirred at RT for 64 h.  The reaction mixture was diluted with water 
(10 mL) and extracted into EtOAc (3 x 10 mL).  The combined organic layers were passed 
through a hydrophobic frit, and concentrated in vacuo.  The crude residue was redissolved in 
CDCl3 and analyzed by 
1
H NMR.
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1
H NMR analysis of the crude materials showed: 
• 0% conversion to 5h against 3,4,5-trichloropyridine (0.094 mmol) as a standard; 
• 0% conversion to 5i against 3,4,5-trichloropyridine (0.066 mmol) as a standard. 
 
Investigating late-stage oxidation under hypervalent iodine conditions
[14]
 
Either melperone hydrochloride (30 mg, 0.10 mmol) or bepridil hydrochloride hydrate (42 
mg, 0.10 mmol) was added to a solution of iodobenzene diacetate (71 mg, 0.22 mmol) in 
THF (0.36 mL).  Water (0.14 mL) was added, and the reaction mixture stirred at RT for 16 h.  
The solvent was evaporated under flow of nitrogen and the crude residue was redissolved in 
CDCl3 and analyzed by 1H NMR.   
1
H NMR analysis of the crude materials showed: 
• 0% conversion to 5h against 3,4,5-trichloropyridine (0.067 mmol) as a standard; 
• 0% conversion to 5i against 3,4,5-trichloropyridine (0.080 mmol) as a standard. 
 
Water was used as a co-solvent in order to try to form phenyliodosobenzene
[15]
 as the oxidant 
in situ.  Comparitive reactions were also carried out using DCM as the solvent, as was used in 
the route described by Waghmode,
[14]
 and also in anhydrous THF to ascertain if the presence 
of water was inhibiting the oxidation, but the reaction profiles were same as with the 
THF/H2O system. 
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NMR Spectra of synthesized compounds 
Crude 
1
H NMR spectra of selected entries during optimization and mechanistic studies 
 
Table S1, entry 7 
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Table S1, entry 8 
 
  
36 
 
Table S1, entry 10 
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Table S1, entry 10 
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Table S2, entry 1 
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Table S2, entry 2 
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Table S2, entry 3 
  
41 
 
Table S2, entry 4 
  
42 
 
Table S2, entry 5 
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Table S2, entry 6 
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Table S2, entry 7 
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1
H NMR spectra of selected crude substrates determining NMR conversions 
 Tert-butyl 4-benzyl-3-oxopiperazine-1-carboxylate 3h 
  
46 
 
 4-Benzyl-1-methylpiperazin-2-one 3i 
  
47 
 
 4-Phenylpiperidin-2-one 3l 
   
48 
 
 Oxo-acrivastine 5d 
  
49 
 
 Oxo-vardenafil 5e 
  
50 
 
 
4.3:1 ratio of a mixture of co-eluting 7-Oxo-azelastine 5g
Į
 and 2-oxo-azelastine 5g
ȕ
 
  
51 
 
 Oxo-bepridil 5j  
52 
 
  1-Methyl-5'-(2-(N-methylsulfamoyl)ethyl)-2'-oxo-1-azaspiro 
[bicyclo[2.2.1]heptane-7,3'-indolin]-1-ium iodide 14 
  
53 
 
Isolated compounds 
 
 1-(4-Methoxybenzyl)piperidine 2b 
 
1
H NMR 
54 
 
 1-(4-Nitrobenzyl)piperidine 2c 
 
1
H NMR 
  
55 
 
 2-Benzyl-1,2,3,4-tetrahydroisoquinoline 2d 
 
1
H NMR 
  
56 
 
 1-Benzylazepane 2f 
 
1
H NMR 
  
57 
 
 1-(p-Tolyl)piperidine 2k 
 
1
H NMR 
  
58 
 
  (R)-1-(1-Phenylethyl)piperidine 2m 
 
1
H NMR 
  
59 
 
 (S)-1-(4-Methoxybenzyl)-3-methylpiperidine 2n 
 
1
H NMR 
  
60 
 
13
C NMR 
  
61 
 
 (2R,6R)-4-(4-Methoxybenzyl)-2,6-dimethylmorpholine 2o 
 
1
H NMR 
  
62 
 
13
C NMR 
  
63 
 
N
  1-(1-Phenylethyl)piperidine 2s 
 
1
H NMR 
  
64 
 
  1-(4-Methoxybenzyl)-3-methylpiperidine 2t 
 
1
H NMR 
  
65 
 
 1-Benzylpiperidin-2-one 3a 
 
1
H NMR 
  
66 
 
13
C NMR 
  
67 
 
 1-(4-Methoxybenzyl)piperidin-2-one 3b 
 
1
H NMR 
  
68 
 
13
C NMR 
  
69 
 
 1-(4-Nitrobenzyl)piperidin-2-one 3c 
 
1
H NMR 
  
70 
 
13
C NMR 
  
71 
 
 2-Benzyl-3,4-dihydroisoquinolin-1(2H)-one 3d 
 
1
H NMR 
  
72 
 
13
C NMR 
  
73 
 
 1-Benzylpyrrolidin-2-one 3e 
 
1
H NMR 
  
74 
 
13
C NMR  
  
75 
 
 1-Benzylazepan-2-one 3f 
 
1
H NMR 
  
76 
 
13
C NMR 
  
77 
 
 4-Benzylmorpholin-3-one 3g 
 
1
H NMR 
  
78 
 
13
C NMR 
  
79 
 
 Tert-butyl 4-benzyl-3-oxopiperazine-1-carboxylate 3h 
 
1
H NMR 
  
80 
 
13
C NMR 
  
81 
 
 4-Benzyl-1-methylpiperazin-2-one 3i 
 
1
H NMR 
  
82 
 
13
C NMR 
  
83 
 
 1-(4-Iodophenyl)piperidin-2-one 3j 
 
1
H NMR 
  
84 
 
13
C NMR 
  
85 
 
 1-(p-Tolyl)piperidin-2-one 3k 
 
1
H NMR  
   
86 
 
13
C NMR  
  
87 
 
 4-Phenylpiperidin-2-one 3l 
 
1
H NMR  
   
88 
 
13
C NMR  
  
89 
 
  (R)-1-(1-Phenylethyl)piperidin-2-one 3m 
 
1
H NMR  
   
90 
 
13
C NMR  
  
91 
 
 (S)-1-(4-Methoxybenzyl)-5-methylpiperidin-2-one 3n
Į 
 
1
H NMR  
  
92 
 
13
C NMR  
  
93 
 
 (S)-1-(4-Methoxybenzyl)-3-methylpiperidin-2-one 3n
ȕ 
 
1
H NMR  
  
94 
 
13
C NMR  
  
95 
 
 (2R,6R)-4-(4-Methoxybenzyl)-2,6-dimethylmorpholin-3-one 3o 
 
1
H NMR  
  
96 
 
13
C NMR  
  
97 
 
 (S)-Ethyl 1-benzyl-5-oxopyrrolidine-2-carboxylate 3p 
 
1
H NMR 
  
98 
 
13
C NMR 
  
99 
 
N
O  1-(1-Phenylethyl)piperidin-2-one 3s 
 
1
H NMR 
  
100 
 
N
O
MeO
  1-(4-Methoxybenzyl)-5-methylpiperidin-2-one 3t
Į
 
 
1
H NMR 
  
101 
 
  1-(4-methoxybenzyl)-3-methylpiperidin-2-one 3t
ȕ
 
 
1
H NMR 
  
102 
 
 Ethyl 1-benzyl-5-oxopyrrolidine-2-carboxylate 3u 
 
1
H NMR 
  
103 
 
 Oxo-rispoeridone 5a 
 
1
H NMR  
   
104 
 
13
C NMR  
   
105 
 
 Oxo-varenicline 5b 
 
1
H NMR  
   
106 
 
13
C NMR  
   
107 
 
 Oxo-nafoxidine 5c 
 
1
H NMR  
   
108 
 
13
C NMR  
   
109 
 
 Oxo-acrivastine 5d 
 
1
H NMR  
   
110 
 
13
C NMR  
   
111 
 
 Oxo-vardenafil 5e 
 
1
H NMR  
   
112 
 
13
C NMR  
   
113 
 
 Oxo-fenpropimorph (diastereomeric mixture) 5f 
1
H NMR  
   
114 
 
13
C NMR  
   
115 
 
 7-Oxo-azelastine 5g
Į
 
 
1
H NMR  
   
116 
 
13
C NMR  
   
117 
 
2-Oxo-azelastine 5g
ȕ
 
 
1
H NMR  
   
118 
 
13
C NMR  
   
119 
 
 Oxo-Melperone 5h 
 
1
H NMR  
   
120 
 
13
C NMR  
   
121 
 
 Oxo-Bepridil 5i 
 
1
H NMR  
   
122 
 
13
C NMR  
   
123 
 
 Oxo-iodo-Bepridil 15 
 
1
H NMR  
   
124 
 
13
C NMR  
   
125 
 
  1-Methyl-5'-(2-(N-methylsulfamoyl)ethyl)-2'-oxo-1-azaspiro 
[bicyclo[2.2.1]heptane-7,3'-indolin]-1-ium iodide 14 
 
1
H NMR  
   
126 
 
13
C NMR  
   
127 
 
 
18
O-1-benzylpiperidin-2-one 
18
O-3a 
 
1
H NMR 
   
128 
 
NaHCO3/H2
18
O reaction LCMS 
 
NaOAc/H2O reaction LCMS 
 
Na
18
OAc/H2O reaction LCMS 
 
Na
18
OAc/H2
18
O reaction LCMS 
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Investigating late-stage oxidation under Milstein conditions 
Applied to substrate 4h 
1
H NMR of crude product 
   
130 
 
High pH LCMS spectrum of reaction mixture 
(Starting material Rt = 1.23 min) 
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Applied to substrate 4i 
1
H NMR of crude product 
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High pH LCMS spectrum of reaction mixture 
(Starting material Rt = 1.67 min) 
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Investigating late-stage oxidation under Emmert conditions 
Applied to substrate 4h 
1
H NMR of crude product 
  
134 
 
High pH LCMS spectrum of reaction mixture 
(Starting material Rt = 1.22 min) 
  
135 
 
Applied to substrate 4i 
1
H NMR of crude product 
  
136 
 
High pH LCMS spectrum of reaction mixture 
(Starting material Rt = 1.68 min) 
  
137 
 
Investigating late-stage oxidation under classical Ru
IV
O2/NaIO4 conditions 
Applied to substrate 4h 
1
H NMR of crude product 
 
138 
 
High pH LCMS spectrum of reaction mixture 
(Starting material Rt = 1.22 min) 
  
139 
 
Applied to substrate 4i 
1
H NMR of crude product 
140 
 
High pH LCMS spectrum of reaction mixture 
(Starting material Rt = 1.67 min) 
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Investigating late-stage oxidation under hypervalent iodine conditions 
Applied to substrate 4h 
1
H NMR of crude product 
 
142 
 
High pH LCMS spectrum of reaction mixture 
(Starting material Rt = 1.21 min) 
  
143 
 
Applied to substrate 4i 
1
H NMR of crude product 
  
144 
 
High pH LCMS spectrum of reaction mixture 
(Starting material Rt = 1.67 min) 
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